

FORM PTO-1390
(REV. 11-2000)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371

11137/04704

U.S. APPLICATION NO. (If known, see 37 CFR 1.5)

09/890167

INTERNATIONAL APPLICATION NO.
PCT/US00/02366INTERNATIONAL FILING DATE
28 January 2000 (28.01.00)PRIORITY DATE CLAIMED
29 January 1999 (29.01.99)

TITLE OF INVENTION

TRANSGENIC PLANTS MODIFIED TO CONTAIN RESVERATROL GLUCOSIDE AND USES THEREOF

APPLICANT(S) FOR DO/EO/US

PAIVA, Nancy L. and HIPSKIND, John D.

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:


1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☐ This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.
4. ☐ The US has been elected by the expiration of 19 months from the priority date (Article 31).
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. ☐ is attached hereto (required only if not communicated by the International Bureau).
 - b. ☐ has been communicated by the International Bureau.
 - c. ☒ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
 - a. ☐ is attached hereto.
 - b. ☐ has been previously submitted under 35 U.S.C. 154(d)(4).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
 - a. ☐ are attached hereto (required only if not communicated by the International Bureau).
 - b. ☐ have been communicated by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☒ have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).
9. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☐ An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11 to 20 below concern document(s) or information included:

11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☒ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☒ A **FIRST** preliminary amendment.
14. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
15. ☐ A substitute specification.
16. ☐ A change of power of attorney and/or address letter.
17. ☒ A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.
18. ☐ A second copy of the published international application under 35 U.S.C. 154(d)(4).
19. ☐ A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
20. ☒ Other items or information: Verified Statement (Déclaration) Claiming Small Entity Status; Statement Under 37 C.F.R. 1.825(a)-(b) and PCT Rule 13ter.2


EXPRESS MAIL NO. EL589917112US DATE OF DEPOSIT 27 July 2001
deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Box PCT, Washington, D.C. 20231 on 27 July 2001 (Date of Deposit)I hereby certify that this correspondence is being
deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Box PCT, Washington, D.C. 20231 on 27 July 2001 (Date of Deposit)

page 1 of 1 Derrick Gordon (Name of Depositor)



(Signature)

Date of Signature: 27 July 2001

U.S. APPLICATION NO. 09/890167 INTERNATIONAL APPLICATION NO. PCT/US00/02366		ATTORNEY'S DOCKET NUMBER 11137/04704		
21. <input checked="" type="checkbox"/> The following fees are submitted: BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)): Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO. \$1000.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$860.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$710.00 International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$690.00 International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) \$100.00 ENTER APPROPRIATE BASIC FEE AMOUNT =		CALCULATIONS PTO USE ONLY <div style="border: 1px solid black; padding: 2px;"> \$ 860.00 </div>		
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).		<div style="border: 1px solid black; padding: 2px;"> \$ </div>		
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	
Total claims	103 - 20 =	83	x \$18.00	
Independent claims	9 - 3 =	6	x \$80.00	
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$270.00	
TOTAL OF ABOVE CALCULATIONS =			\$ 3104	
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.			+ <div style="border: 1px solid black; padding: 2px;"> 1552 </div>	
SUBTOTAL =			\$ 1552	
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).			<div style="border: 1px solid black; padding: 2px;"> \$ </div>	
TOTAL NATIONAL FEE =			\$ 1552	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +			<div style="border: 1px solid black; padding: 2px;"> 80 </div>	
TOTAL FEES ENCLOSED =			\$ 1632	
			Amount to be refunded:	\$
			charged:	\$
a. <input type="checkbox"/> A check in the amount of \$ _____ to cover the above fees is enclosed. b. <input checked="" type="checkbox"/> Please charge my Deposit Account No. <u>18-1260</u> in the amount of \$ 1632.00 to cover the above fees. A duplicate copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>18-1260</u> . A duplicate copy of this sheet is enclosed. d. <input type="checkbox"/> Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.				
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137 (a) or (b)) must be filed and granted to restore the application to pending status.				
SEND ALL CORRESPONDENCE TO: Eugenia S. HANSEN Sidley Austin Brown & Wood 717 N. Harwood, Suite 3400 Dallas, Texas 75201 United States of America		<div style="text-align: center;">  SIGNATURE Karen L. KNEZEK NAME <u>39,253</u> REGISTRATION NUMBER </div>		

Applicant or Patentee: **Nancy L. Paiva, et al.**

Serial or Patent No.: **Unassigned**

Filed or Issued:

Attorney Docket No.: **11137/04704**

For: **TRANSGENIC PLANTS MODIFIED TO CONTAIN RESVERATROL
GLUCOSIDE AND USES THEREOF**

**VERIFIED STATEMENT (DECLARATION)
CLAIMING SMALL ENTITY STATUS
(37 C.F.R. §§ 1.9(f) and 1.27(d))
NONPROFIT ORGANIZATION**

I hereby declare that I am an official empowered to act on behalf of the nonprofit organization identified below:

NAME OF ORGANIZATION: **The Samuel Roberts Noble Foundation, Inc.**

ADDRESS OF ORGANIZATION: 2510 Sam Noble Parkway, Ardmore, Oklahoma 73402

TYPE OF ORGANIZATION

- () UNIVERSITY OR OTHER INSTITUTE OF HIGHER EDUCATION
- (X) TAX EXEMPT UNDER INTERNAL REVENUE SERVICE CODE (26 U.S.C. §§ 501(a) and 501(c)(3))
- () NONPROFIT SCIENTIFIC OR EDUCATIONAL UNDER STATUTE OF STATE OF THE UNITED STATES OF AMERICA
(NAME OF STATE)
(CITATION OF STATUTE)
- () WOULD QUALIFY AS TAX EXEMPT UNDER INTERNAL REVENUE SERVICE CODE (26 U.S.C. §§ 501(a) AND 501(c)(3)) IF LOCATED IN THE UNITED STATES OF AMERICA
- () WOULD QUALIFY AS NONPROFIT SCIENTIFIC OR EDUCATIONAL UNDER STATUTE OF STATE OF THE UNITED STATES OF AMERICA IF LOCATED IN THE UNITED STATES OF AMERICA
(NAME OF STATE)
(CITATION OF STATUTE)

I hereby declare that the nonprofit organization identified above qualifies as a nonprofit organization as defined in 37 C.F.R. § 1.9(e) for purposes of paying reduced fees under §§ 41(a) and (b) of Title 35, United States Code, with regard to the invention entitled **TRANSGENIC PLANTS MODIFIED TO CONTAIN RESVERATROL GLUCOSIDE AND USES THEREOF** by inventors **Nancy L. Paiva and John D. Hipskind** described in

- ☐ the specification filed herewith.
- ☒ PCT International Application No. PCT/US00/02366, filed January 28, 2000.
- ☐ patent no. , issued .

I hereby declare that rights under contract or law have been conveyed to and remain with the nonprofit organization regarding the above-identified invention.

If the rights held by the nonprofit organization are not exclusive, each individual, concern or organization having rights in the invention is listed below* and that no rights to the invention are held by any person, other than the inventor, who would not qualify as an independent inventor under 37 C.F.R. § 1.9(c) if that person made the invention, or by any concern which would not qualify as a small business concern under 37 C.F.R. § 1.9(d) or a nonprofit organization under 37 C.F.R. § 1.9(e).

Each person, concern or organization having any rights in the invention is listed below:

- ☒ no such person, concern or organization
- ☐ persons, concerns or organizations listed below*

*NOTE: Separate verified statements are required from each named person, concern, or organization having rights to the invention averring to their status as small entities. (37 C.F.R. § 1.27)

NAME: N/A

ADDRESS:

☐ individual ☐ small business concern ☐ nonprofit organization

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 C.F.R. § 1.28(b))

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are

punishable by fine or imprisonment, or both, under § 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING: **Michael A. Cawley**

TITLE IN ORGANIZATION: **President and CEO**

ADDRESS OF PERSON SIGNING: **2510 Sam Noble Parkway, Ardmore OK 73401**

SIGNATURE Michael A. Cawley

DATE 17 July 01

10/22/01 10:00:00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
U.S. DESIGNATED/ELECTED OFFICE (DO/EO/US)
FOR THE PATENT COOPERATION TREATY

In re application of:

Nancy L. PAIVA, et al.

For:

**TRANSGENIC PLANTS MODIFIED TO CONTAIN
RESVERATROL GLUCOSIDE AND USES THEREOF**

Application Serial No.

Unassigned

Filing Date:

Concurrently herewith

International

Filing Date:

28 January 2000

International


Application No:

PCT/US00/02366

Assistant Commissioner for Patents
Box PCT
Washington, D.C. 20231

EXPRESS MAIL NO. EL589917112US DATE OF DEPOSIT 27 July 2001
I hereby certify that this correspondence is being deposited with the United States
Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10
on the date indicated above and is addressed to the Assistant Commissioner for
Patents, Box PCT, Washington, D.C. 20231 on 27 July 2001
(Date of Deposit)

Derrick Gordon
Name of Depositor



Signature

Date of Signature: 27 July 2001

Dear Sir:

PRELIMINARY AMENDMENT

This Preliminary Amendment is being filed concurrently with a patent application under
35 U.S.C. 371 of International Application Serial No. PCT/US00/02366. In accordance with 37
C.F.R. §1.121(c)(1), please amend the above-identified application as follows:

IN THE CLAIMS

Please delete Claims 43-57.

IN THE SEQUENCE LISTING

An amended Sequence Listing is being filed concurrently herewith in paper copy and in
computer readable form. The Sequence Listing has been amended to delete THE SAMUEL

ROBERTS NOBLE FOUNDATION, INC. as an applicant and to change the ATTORNEY DOCKET NO. to 11137/04704. A Statement Under 37 C.F.R. §1.825(a) and (b) and PCT Rule 13^{ter}.2 is also being filed concurrently herewith. Applicant requests that the amended Sequence Listing be entered into the case.

CONCLUSION

Claims 1-57 as presented in the annex to the International Preliminary Examination Report are pending. Applicants have cancelled Claims 43-57 and present Claims 1-42 without amendment.

Payment for the fees associated with these claims has been directed on the Transmittal Letter to the United States Designated/Elected Office Concerning a Filing Under 35 U.S.C. §371 filed concurrently herewith.

Respectfully submitted

By: Karen L. Knezek
Karen L. Knezek
Registration No.39, 253

KLK:aep:ld

27 July 2001

SIDLEY AUSTIN BROWN & WOOD

717 North Harwood, Suite 3400

Dallas, Texas 75201-6507

214-981-3300

214-981-3400 (fax)

**TRANSGENIC PLANTS MODIFIED TO CONTAIN
RESVERATROL GLUCOSIDE AND USES THEREOF**

TECHNICAL FIELD OF INVENTION

5 This invention relates to transgenic plants and plant cells modified to accumulate resveratrol glucoside or to contain increased levels thereof.

BACKGROUND OF THE INVENTION


10 Stilbenes are biologically active phenolic compounds exhibiting a broad spectrum of antibiotic and pharmacological activities, and plants modified with respect to stilbene content may useful for various purposes. Diverse plants and plant families naturally produce stilbenes, including grape (Vitaceae), Scots pine (Cyperaceae), tall fescue (Poaceae), and peanut (Arachaceae) (Sotheeswaran, S. and Pasupathy, V. 1993. "Distribution of resveratrol oligomers in plants," *Phytochemistry* 32:1083-1092; Powell, et al. 1994. "Isolation of resveratrol from *Festuca versuta* and evidence of the widespread occurrence of this stilbene in the
15 *Poaceae*," *Phytochemistry* 35:335-338; Ingram, J.L. 1976. "3,5,4'-Trihydroxystilbene as a phytoalexin from groundnut (*Arachis hypogaea*). *Phytochemistry* 15,1791-1793).

20 Stilbenes have been reported to play a role in plant resistance to fungal pathogens. Constitutive stilbene accumulation is believed to function as a mechanism of general resistance to microbial pathogens, while in some plants, stilbenes accumulate as phytoalexins in response to microbial attack.

25 Further, stilbenes are thought to have health-promoting effects, and plants containing stilbenes may be desirable in human and animal diets. Stilbenes have been shown to have a number of beneficial effects on human health, based on epidemiological studies and laboratory studies involving humans, animals, cell cultures and enzyme assays (Jang, et al. 1997. "Cancer chemopreventative activity of resveratrol, a natural product derived from grapes," *Science* 275:218-220).

Of particular interest is the stilbene resveratrol. Resveratrol is present in wine and may be involved in the health-promotive effects of moderate wine consumption. The increased consumption of resveratrol has been proposed as a way to reduce cancer rates and coronary heart disease in humans (Soleas, et al. 1997. "Wine as a biological fluid: history, production, and role in disease prevention," *J Clin Lab Anal* 11: 287-313). Resveratrol and plant extracts containing resveratrol have been shown to be effective in prevention and therapy of atherosclerosis (Arichi, et al. 1982. *Chem Pharm Bull* 30:1766), as an anti-inflammatory agent (Kimura, et al. 1985. *Biochem Biophys Acta* 834:275), and as an anti-hyperoxidative agent (Kimura, et al. 1983. *Plant Med J Med Plant Res* 49:51). Resveratrol showed significant inhibition of aberrant colon crypt formation in a carcinogen (azoxymethane) treated rat model, suggesting utility in inhibiting tumorigenesis in humans (Steele, et al. 1998. "Cancer chemoprevention drug development strategies for resveratrol," *Pharm Bio* 36:62-68 suppl). Resveratrol has also been found to promote the formation of nitroxides which are effective as vasodilatory agents and in inhibiting platelet aggregation (Fitzpatrick, et al. 1993. *Am J Physiol* 34:774).

Resveratrol has the following chemical structure:



The biosynthetic pathway of resveratrol in plants involves stilbene synthase. Resveratrol is formed when stilbene synthase converts one molecule of p-coumaroyl-CoA and three molecules of malonyl-CoA into resveratrol, i.e., 3,5,4'-trihydroxystilbene. In some plant species, resveratrol production is inducible, and resveratrol accumulates as a phytoalexin following microbial attack (Langcake, P. and Pryce, R.J. 1976. "The production of resveratrol by *Vitis vinifera* and other members of the Vitaceae as a response to infection or injury," *Physiol Plant*

Pathol 9:77-86; Dercks, et al. 1995. "Stilbene phytoalexins and disease resistance in *Vitis*." In *Handbook of Phytoalexin Metabolism and Action*, M. Daniel and R.P. Purkayastha, eds, Marcel Dekker, Inc. USA, pp. 287-315).


Not all plants naturally accumulate resveratrol or other stilbenes.

5 Heterologous accumulation of resveratrol has been achieved in plants which do not naturally accumulate resveratrol by genetic engineering to express resveratrol synthase. For example, transformation of tobacco with a resveratrol synthase (*RS*) genomic clone from peanut resulted in the rapid accumulation of resveratrol following treatment of cell suspension cultures with fungal elicitor (Hain, et al.
10 1990. "Expression of a stilbene synthase gene in *Nicotiana tabacum* results in synthesis of the phytoalexin resveratrol," *Plant Mol Biol* 15:325-335). Subsequent experiments with an *RS* gene (*VstI*) from *V. vinifera* L. demonstrated a significant level of resistance in transgenic tobacco, tomato, and rice to fungal pathogens *Botrytis cinerea*, *Phytophthora infestans*, and *Pyricularia oryzae*,
15 respectively [Hain et al. 1993. "Disease resistance results from foreign phytoalexin expression in a novel plant," *Nature* 361:153-156; Thomzik, et al. 1997. "Synthesis of a grapevine phytoalexin in transgenic tomatoes (*Lycopersicon esculentum* Mill.) conditions resistance against *Phytophthora infestans*," *Physiol Mol Plant Path* 51:265-278; Stark-Lorenzen, et al. 1997. "Transfer of a grapevine
20 stilbene synthase gene to rice (*Oryza sativa* L.)," *Plant Cell Rep* 16:668-673]. These reports demonstrated that accumulation of resveratrol in foreign plant species transformed with a resveratrol synthase gene provides a means by which a broad spectrum of increased resistance to fungal pathogens can be achieved in any plant. Increased resistance to fungal pathogens, in turn, results in increased crop
25 production and reduction in the use of crop protection chemicals.


Accumulation of resveratrol has also been reported to have some negative side effects in plants. For example, Fischer, et al. reported that plants accumulating increased levels of resveratrol were rendered male sterile. Not only was the pollen destroyed, but the plants also demonstrated lower seed yields and
30 altered flower color (Fischer, et al. 1997. "Stilbene synthase gene expression

causes changes in flower colour and male sterility in tobacco," *Plant J* 11:489-498).

Resveratrol-3-O- β -D-glucopyranoside (3,4',5-trihydroxystilbene-3- β -D-glucoside, polydatin, piceid; hereinafter referred to as "resveratrol glucoside" or "RGluc") is a resveratrol conjugate. The chemical structure for the trans and cis isomers are given below.



trans isomer



cis isomer

Both trans- and cis-RGluc have been isolated from nontransgenic plants, for example, grapes (Jeandet, et al. 1994. "Occurrence of a resveratrol- β -D-glucoside in wine: preliminary studies," *Vitis* 33:183-184), *Eucalyptus sideroxylon* wood (Hillis, et al. 1974. "Polyphenols of *Eucalyptus sideroxylon* wood," *Phytochemistry* 13:1591-1595), and Norway spruce (Alcubilla-Martin, M. 1970. "Extraction, chromatographic separation, and isolation of fungistatic

substances from the inner bark of Norway spruce," *Z. Pflanzenernaehr. Bodenk.* 127:64-74).

It has been reported that human benefits previously thought to be due to resveratrol are also attributable to RGluc. For example, in International Application WO 9958119, a method for preventing or treating restenosis, a medical condition characterized by recurrent stricture of a heart valve, and for preventing the recurrence or progression of coronary heart disease was provided which involves administration of an active agent comprising cis-resveratrol, trans-resveratrol, a mixture thereof, or a pharmacologically acceptable salt, ester, amide, prodrug, or analog thereof. Both cis- and trans-resveratrol glucoside (RGluc) were listed among the active agents, and the patent discloses these compounds as being either naturally occurring or chemically synthesized in the laboratory.

Subsequent to the epidemiological and biochemical studies which indicated that the resveratrol in wine was at least in part providing valuable protection against cardiovascular disease, numerous labs detected high levels of RGluc in several red and white wines. In view of these findings, it was reported that RGluc likely contributes to the human health benefit of wines (Goldberg, et al. 1996. "Resveratrol glucosides are important components of commercial wines," *Am J Enolog and Viticulture* 47:415-420).

The present invention describes transgenic plants and plant cells that have been modified to contain heterologous RGluc, as well as use of such plants or plant cells in manufacturing foods, nutritional supplements, animal feed supplements, nutraceuticals, and pharmaceuticals to serve as nutritional and therapeutic elements in human and animal diets.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1A and 1B (SEQ ID NO:1) depict the sequence of the promoter + resveratrol synthase coding region + terminator cassette (*Hind*III partial digestion fragment) which was transferred into the *Hind*III site of the T-DNA region of

pGA482, preparing it for *Agrobacterium*-based transfer to plant cells. FIG. 1A contains bases 1-1920, and FIG. 1B contains bases 1921-3089. *Hind*III restriction enzyme sites are found at bases 1 to 6 and 3084 to 3089 (indicated by “*”). A *Nco*I restriction enzyme site is found at bases 902 to 907 (indicated by “†”). A *Bam*HI restriction enzyme site is found at bases 2849 to 2854 (indicated by “■”). Bases 1 to 901 contain the CaMV promoter (with duplicated enhancer element) and TEV untranslated region from pRTL2. Bases 902 to 2854 contain the *Nco*I (partial digest) and *Bam*HI (complete digest) restriction enzyme generated fragment from the RS cDNA clone (indicated by underlining). Bases 904 to 2064 contain the coding region of the RS protein (indicated by italics), and the amino acid sequence is given in SEQ ID NO:2. Bases 2855 to 3089 contain the CaMV untranslated region from pRTL2.

FIG. 2 is a schematic drawing of the vector constructs used in this method: double CaMV35S:RS binary vector containing a resveratrol synthase cDNA from peanut.

FIG. 3A and FIG. 3B are a composite photo of the autoradiography results of Northern blot analysis (RNA gel blot analysis) indicating comparative levels of resveratrol synthase (RS) to chalcone synthase (CHS) transcript levels in the leaves, internodes and roots. FIG. 3A depicts RS transcript levels total RNA (10 µg/lane) extracted from leaves, internodes and roots of three independently transformed alfalfa lines (lanes 1-3) and one control line (C=pGA482 vector control plant). FIG. 3B depicts the same total RNA extracts hybridized with an alfalfa CHS cDNA probe. In both experiments (FIG. 3A and FIG. 3B), hybridization with an 18S ribosomal RNA probe (18S) served as a loading control.

FIG. 4 is the data from the reverse phase (C18) HPLC analysis of crude acetone extracts of transgenic alfalfa plants revealing the unknown compound later identified as RGluc in the CaMV35S:RS transformed alfalfa line (chromatogram A) that is not present in a pGA482 binary vector control plant

(chromatogram B). RGluc eluted at approximately 8.2 minutes under these conditions.

FIG. 5 is the UV absorbance spectra of the unknown compound later identified as RGluc compared to a known resveratrol standard.

5 FIG. 6 is the HPLC chromatogram of the putative resveratrol-conjugate following treatment with beta-glucosidase revealing the release of the resveratrol aglycone. Identity was confirmed by co-chromatography with an authentic resveratrol standard.

10 FIG. 7 depicts a representative alfalfa shoot labeled to illustrate leaf and internode designation used in the analysis of CaMV35S:RS transformed lines (L=leaves; I= internodes).

15 FIG. 8 is a graph of the results from HPLC quantitation of RGluc in leaves and internodes along shoots from a CaMV35S:RS transformed line revealing the age-and tissue-dependent accumulation of RGluc represented in terms of microgram resveratrol aglycone equivalents per gram of tissue.

20 FIG. 9 is a composite photo of the autoradiography results of Northern blot analysis (RNA get blot analysis) indicating resveratrol synthase (RS) transcript levels in the leaves and internodes relative to the age or tissue type, compared to an 18S ribosomal RNA probe (18S) served as a locating control (total RNA=10 µg/lane), indicating that the RS cDNA transcript is produced in all of these transgenic alfalfa tissues.

25 FIG. 10 is a graph depicting the quantitation of necrotic lesion area in leaves of control (pGA482-transformed plant C-F2) and RGluc-accumulating (CaMV 35S-RS construct transformed plant 35S:RS-D1) plants after wound-inoculation with the alfalfa fungal pathogen *Phoma medicaginis*. The points show the average necrotic lesion size (mm²) surrounding the wound site at four different inoculum levels (CFU/ml) measured at 10 days post-inoculation in the

transformed CaMV35S:RS and pGA482 vector control plants. The error bars represent the standard deviation of the mean.

FIG. 11 is a graph depicting the quantitation of necrotic lesion area in leaves of control (pGA482-transformed plant C-A1.2) and RGluc-accumulating (CaMV35S-RS construct transformed plant 35S:RS-E2.1) plants after wound-inoculation with the alfalfa fungal pathogen *Phoma medicaginis*. The points show the average necrotic lesion size (mm^2) surrounding the wound site at four different inoculum levels (CFU/ml) measured at 10 days post-inoculation in the transformed CaMV35S:RS and pGA482 vector control plants. The error bars represent the standard deviation of the mean.

FIG. 12A - FIG. 12D is a composite photograph of leaves of RGluc-accumulating plants and the control alfalfa after wound-inoculation with the alfalfa fungal pathogen *Phoma medicaginis* showing the development of fungal necrotic lesions and reproductive structures (pycnidia). FIG. 12A depicts a pGA482 vector control plant leaf at 10 days post-inoculation (CFU/ml=10,000). FIG. 12B depicts a transformed CaMV35S:RS RGluc-accumulating plant leaf at 10 days post-inoculation (CFU/ml=10,000). FIG. 12C depicts trypan blue staining of the inoculated control line showing numerous pycnidia (dark roundish spots) and hyphae (thin dark lines radiating outward from inoculation hole). Wound-inoculated leaves were detached from stems after 10 days then placed at 100% relative humidity for three days before staining. FIG 12D depicts trypan blue staining of the inoculated CaMV35S:RS RGluc-accumulating line showing no pycnidia or hyphae beyond the inoculation wound site. Wound-inoculated leaves were detached from stems after 10 days then placed at 100% relative humidity for three days before staining.

FIG. 13A and 13B are graphs comparing the extent of hyphal ingress to the number of pycnidia in control alfalfa leaves (FIG. 13A) and RGluc CaMV5S:RS-transformed leaves (FIG. 13B). Following trypan blue staining, the total area of hyphal growth was measured and the number of pycnidia scored in

inoculated leaves (CFU/ml=10,000) from the control and CaMV35S:RS lines. For this experiment, the number of lesions measured for control and CaMV35S:RS were n=50 and n=57, respectively.

FIG. 14 is a HPLC chromatogram of an extract from a transgenic soy callus transformed with the construct described in Fig. 2. The RGluc peak is marked by "*".

FIG. 15 is a HPLC chromatogram of an extract from a non-transgenic soy callus.

FIG. 16 is the ultra-violet diode array scan of the soybean callus-generated RGluc peak.

FIG. 17 is a HPLC chromatogram which demonstrates RGluc partially purified from transgenic soybean callus before treatment with beta-glucosidase.

FIG. 18 is a HPLC chromatogram which demonstrates partially purified RGluc after brief treatment with beta-glucosidase.

SUMMARY OF THE INVENTION

In one aspect, the present invention is a food comprising edible transgenic plant material capable of being ingested for its nutritional value, wherein the transgenic plant is transformed with a portion of a resveratrol synthase gene and exhibits increased levels of resveratrol glucoside when compared to levels of resveratrol glucoside in plants of the same species which do not comprise the portion of a resveratrol synthase gene. The transgenic plant can be transformed with a resveratrol synthase gene construct. Exemplary transformed plants include legumes. Exemplary legumes include alfalfa and soybean.

In another aspect, the present invention is a food comprising resveratrol glucoside isolated from an edible transgenic plant which is transformed with a portion of a resveratrol synthase gene and exhibits increased levels of resveratrol

glucoside when compared to levels of resveratrol glucoside in plants of the same species which do not comprise the portion of a resveratrol synthase gene. The transgenic plant can be transformed with a resveratrol synthase gene construct. Exemplary transformed plants include legumes. Exemplary legumes include alfalfa and soybean.

In another aspect, the present invention is an edible composition comprising at least a portion of an edible transgenic plant which is transformed with a portion of a resveratrol synthase gene and exhibits increased levels of resveratrol glucoside when compared to levels of resveratrol glucoside in plants of the same species which do not comprise the portion of a resveratrol synthase gene, wherein the composition is suitable for ingestion as a food stuff, a nutritional supplement, an animal feed supplement, or a nutraceutical. The transgenic plant can be transformed with a resveratrol synthase gene construct. Exemplary transformed plants include legumes. Exemplary legumes include alfalfa and soybean.

In another aspect, the present invention is a composition comprising resveratrol glucoside suitable for administration as a food stuff, a nutritional supplement, an animal feed supplement, a nutraceutical, or a pharmaceutical, wherein the resveratrol glucoside is isolated from at least a portion of an edible transgenic plant which is transformed with a portion of a resveratrol synthase gene and exhibits increased levels of resveratrol glucoside when compared to levels of resveratrol glucoside in plants of the same species which do not comprise the portion of a resveratrol synthase gene. The transgenic plant can be transformed with a resveratrol synthase gene construct. Exemplary transformed plants include legumes. Exemplary legumes include alfalfa and soybean.

In another aspect, the present invention is an edible transgenic plant transformed with a portion of a resveratrol synthase gene, wherein the transformed plant exhibits increased levels of resveratrol glucoside when compared to levels of resveratrol glucoside in plants of the same

species which do not comprise the portion of a resveratrol synthase gene. The transgenic plant can be transformed with a resveratrol synthase gene construct.

5 In another aspect, the present invention is seed from an edible transgenic plant transformed with a portion of a resveratrol synthase gene, wherein the transformed plant exhibits increased levels of resveratrol glucoside when compared to levels of resveratrol glucoside in plants of the same species which do not comprise the portion of a resveratrol synthase gene. The transgenic plant can be transformed with a resveratrol synthase gene construct.

10 In another aspect, the present invention is progeny from an edible transgenic plant transformed with a portion of a resveratrol synthase gene, wherein the transformed plant exhibits increased levels of resveratrol glucoside when compared to levels of resveratrol glucoside in plants of the same species which do not comprise the portion of a resveratrol synthase gene. The transgenic
15 plant can be transformed with a resveratrol synthase gene construct.

In another aspect, the present invention is progeny from seed of an edible transgenic plant transformed with a portion of a resveratrol synthase gene, wherein the transformed plant exhibits increased levels of resveratrol glucoside when compared to levels of resveratrol glucoside in plants of the same species
20 which do not comprise the portion of a resveratrol synthase gene. The transgenic plant can be transformed with a resveratrol synthase gene construct.

In another aspect, the present invention is a method of increasing the nutritional value of an edible plant by transforming the plant with a portion of a resveratrol synthase gene, wherein the transformed plant exhibits increased levels
25 of resveratrol glucoside when compared to levels of resveratrol glucoside in plants of the same species which do not comprise the portion of a resveratrol synthase gene. The transgenic plant can be transformed with a resveratrol synthase gene construct.

In another aspect, the present invention is a method of using an edible transgenic plant transformed with a portion of a resveratrol synthase gene, wherein the plant exhibits increased levels of resveratrol glucoside when compared to levels of resveratrol glucoside in plants of the same species which do not comprise the portion of a resveratrol synthase gene, to provide a nutraceutical benefit to a human or animal administered the resveratrol glucoside. The transgenic plant can be transformed with a resveratrol synthase gene construct. Preferably, the resveratrol glucoside is administered by ingestion of at least a portion of the plant. Alternately, the resveratrol glucoside is administered by ingestion of a composition comprising resveratrol glucoside isolated from the plant.

In another aspect, the present invention is a method of using resveratrol glucoside isolated from an edible transgenic plant transformed with a portion of a resveratrol synthase gene, wherein the plant exhibits increased levels of resveratrol glucoside when compared to levels of resveratrol glucoside in plants of the same species which do not comprise the portion of a resveratrol synthase gene, to provide a pharmaceutical benefit to a patient administered the resveratrol glucoside. The transgenic plant can be transformed with a resveratrol synthase gene construct.

In another aspect, the present invention is a method for creating a transgenic plant comprising an increased level of resveratrol glucoside, comprising transforming a plant with a portion of a resveratrol synthase gene to form a transgenic plant, wherein the transgenic plant exhibits increased levels of resveratrol glucoside when compared to levels of resveratrol glucoside in plants of the same species which do not comprise the portion of a resveratrol synthase gene. Preferably, the plant is transformed by introducing an expression cassette comprising a transcribable DNA fragment, wherein the DNA fragment comprises resveratrol synthase cDNA. Exemplary transformed plants include legumes. Exemplary legumes include alfalfa and soybean.

In another aspect, the present invention is a method of increasing disease resistance in an edible plant by transforming the plant with a portion of a resveratrol synthase gene, wherein the transformed plant exhibits increased levels of resveratrol glucoside when compared to levels of resveratrol glucoside in plants of the same species which do not comprise the portion of a resveratrol synthase gene. The transgenic plant can be transformed with a resveratrol synthase gene construct.

In another aspect, the present invention is a method of decreasing spoilage of an edible plant or plant part after harvesting by transforming the plant or plant part with a portion of a resveratrol synthase gene, wherein the transformed plant or plant part exhibits increased levels of resveratrol glucoside when compared to levels of resveratrol glucoside in plants of the same species which do not comprise the portion of a resveratrol synthase gene. The transgenic plant can be transformed with a resveratrol synthase gene construct.

In another aspect, the present invention is an edible transgenic plant comprising at least one recombinant DNA sequence encoding a portion of a resveratrol synthase gene, wherein the plant, upon expression of the gene, exhibits increased levels of resveratrol glucoside when compared to levels of resveratrol glucoside in plants of the same species which do not comprise said recombinant DNA sequence.

In another aspect, the present invention is a seed from an edible transgenic plant comprising at least one recombinant DNA sequence encoding a portion of a resveratrol synthase gene, wherein the plant, upon expression of the gene, exhibits increased levels of resveratrol glucoside when compared to levels of resveratrol glucoside in plants of the same species which do not comprise the same recombinant DNA sequence.

In another aspect, the present invention is progeny from an edible transgenic plant comprising at least one recombinant DNA sequence encoding a portion of a resveratrol synthase gene, wherein the plant, upon expression of the

gene, exhibits increased levels of resveratrol glucoside when compared to levels of resveratrol glucoside in plants of the same species which do not comprise the same recombinant DNA sequence.

5 In another aspect, the present invention is progeny from seed of an edible transgenic plant comprising at least one recombinant DNA sequence encoding a portion of a resveratrol synthase gene, wherein the plant, upon expression of the gene, exhibits increased levels of resveratrol glucoside when compared to levels of resveratrol glucoside in plants of the same species which do not comprise the same recombinant DNA sequence.

10 In another aspect, the present invention is the use of an edible transgenic plant transformed with a portion of a resveratrol synthase gene, wherein the plant exhibits increased levels of resveratrol glucoside when compared to levels of resveratrol glucoside in plants of the same species which do not comprise the portion of a resveratrol synthase gene, for the preparation of a nutraceutical
15 preparation for achieving a nutritional effect. The transgenic plant can be transformed with a resveratrol synthase gene construct.

In another aspect, the present invention is the use of an edible transgenic plant transformed with a portion of a resveratrol synthase gene, wherein the plant exhibits increased levels of resveratrol glucoside when compared to levels of
20 resveratrol glucoside in plants of the same species which do not comprise the portion of a resveratrol synthase gene, for the preparation of a pharmaceutical preparation for achieving a therapeutic effect. The transgenic plant can be transformed with a resveratrol synthase gene construct.

DETAILED DESCRIPTION

25 The present invention provides for transformation of plants or plant cells which do not normally accumulate stilbenes with a portion of a resveratrol synthase gene wherein the transgenic plants exhibit increased levels of resveratrol glucoside ("RGluc") when compared to levels of resveratrol glucoside in plants of

the same species which do not comprise that same portion of a resveratrol synthase gene. Such plants include dicots and monocots, including but not limited to alfalfa, soybean, tomato, lettuce, tobacco, corn, maize, cotton, squash, beans and other legumes, melons, broccoli and other cole crops, stone fruits, citrus fruits, and strawberries. In the present invention, unless otherwise stated, as used herein, the term "plant" or "progeny" includes plant parts, plant tissue, plant cells, plant protoplasts, plant cell tissue cultures from which plants can be regenerated, plant calli, plant clumps, explants, plant cells that are intact in plants, or parts of plants, such as embryos, pollen, ovules, flowers, capsules, stems, leaves, seeds, roots, root tips, and the like.

A transgenic plant which has accumulated RGluc is useful in improving human and animal nutrition. Edible transgenic plants high in RGluc can be utilized as food for humans and animals. Edible compositions high in RGluc can also be made by incorporation of the transgenic plants or plant materials, or by incorporation of RGluc isolated from the transgenic plants. Compositions useful for administration as a food stuff, a nutritional supplement, an animal feed supplement, a nutraceutical, or a pharmaceutical can be made by incorporation of the transgenic plants or plant materials, or by incorporation of RGluc isolated from the transgenic plants. The nutritional value of a plant can be increased by transforming the plant with a portion of a resveratrol synthase gene and, as a result, accumulating high amounts of RGluc in the plant. Disease resistance can be increased in the transgenic plant by the accumulation of high levels of RGluc upon expression of a resveratrol synthase gene. Likewise, spoilage of transgenic plants or plant parts can be decreased by the accumulation of high levels of RGluc upon expression of a resveratrol synthase gene.

Preferably, RGluc is administered orally by directly ingesting the transgenic plant. Alternatively, RGluc can be isolated from transgenic plants to be used as a crude extract or purified compound. Administration of transgenically produced RGluc to humans or animals provides enhanced pharmaceutical and nutraceutical effects, including but not limited to benefits received from an

antioxidant, platelet aggregation inhibitor, arachidonate metabolism inhibitor, protein kinase inhibitor, inducer of apoptotic cell death in tumor cells, estrogen receptor antagonist, inhibitor of ribonucleotide reductase, tumor initiation inhibitor, tumor promotion inhibitor, tumor progression and differentiation inhibitor, inhibitor of COX-2 and COX-2 induction, lipoprotein synthesis and release modulator as well as other beneficial effects. Transgenically-produced RGluc is also useful as a ultraviolet light protectant, an ultra-violet stabilizer for biocontrol agents, and an agent in the storage of photochemical energy. Based upon RGluc's role in conferring resistance to plants against fungal pathogens, transgenically produced RGluc can also have applications as an antifungal and antibacterial agent in humans.

Transgenically produced RGluc confers disease resistance to heterologous plants that otherwise do not produce stilbenes or do not constitutively accumulate RGluc and do not, therefore, enjoy the benefits of stilbenes. A plant transgenically altered to comprise a resveratrol synthase gene can generate and accumulate RGluc prior to adverse conditions, including but not limited to infection by a pathogen. Thus, RGluc can be used to improve crop yield and quality of food and other plant products.

The structural differences between RGluc and free resveratrol provides increased chemical stability in RGluc. In particular, the glucose on the 3-hydroxyl of RGluc reduces the potential for oxidation of the aglycone by acting as a protecting group for this hydroxyl and reducing the oxidation potential of the dioxygenated ring, relative to the analogous portion of resveratrol. Consequently, RGluc is less subject to oxidation than is resveratrol. RGluc's decreased potential for oxidation provides advantages over resveratrol both in vitro and in vivo: (1) decreased oxidation by air resulting in increased storage stability in vitro; (2) decreased oxidation by peroxidases, oxygen, peroxides, and other processes in living plant cells, potentially resulting in improved disease resistance in transgenic plants; and (3) decreased oxidation by peroxidases, oxygen, peroxides, and other processes during consumption by humans or animals, potentially resulting in

improved health benefits. In plants, glycosylated compounds are also stored in plant vacuoles, leading to further stability of RGluc against oxidation.

RGluc is also preferable to free resveratrol in human and animal diets. Under certain conditions, it is believed that RGluc can be biologically active, or can be readily hydrolyzed into the biologically active form. RGluc is readily convertible to resveratrol by beta-glucosidase, by other glucosidases, or by non-enzymatic hydrolysis, such as by acid hydrolysis. It is believed that RGluc will be absorbed in the digestive system as readily or more readily than free resveratrol, as is the case for numerous sugar derivatives of pharmaceuticals in comparison to the corresponding aglycones. It is further believed that RGluc is hydrolyzed to free resveratrol before or after absorption in the mammalian digestive tract. Therefore, plants which contain RGluc provide a stable dietary source of resveratrol.

The methods of producing RGluc from transgenic plants or cells from transgenic plants as presented herein provide advantages over production methods which utilized nontransgenic plants in which RGluc occurs naturally. Few RGluc-producing nontransgenic plants have been identified, and of these, many are not appropriate for general human or animal consumption. The present invention expands RGluc production to a wide variety of edible plants, resulting in (1) increased sources for the procurement of RGluc producing plants; (2) a larger growing region for RGluc-producing plants which potentially leads to increased production; (3) reduction in seasonal and/or climate limitations associated with nontransgenic RGluc-producers; and (4) increased consumer satisfaction.

In the present invention, a plant which does not normally accumulate stilbenes is transformed with a portion of a resveratrol synthase gene, leading to the uptake of a DNA fragment comprising the resveratrol synthase coding region from either a resveratrol synthase (RS) cDNA or genomic clone, and subsequent generation of RGluc in the plant. In the present invention, whole plants or tissue explants can be transformed. Transformed cells can be fully regenerated into

intact plants or cultured as plant cell callus cultures, or plant cell suspension cultures.

In general, an RS coding region is selected. Resveratrol synthase cDNAs useful in the present invention can be obtained from mRNA isolated from any natural source. For example, a cDNA from peanut can preferably be used to generate RGluc. Any plant known to produce resveratrol, RGluc, or other resveratrol derivatives may also serve as sources of suitable cDNAs, or coding sequences may be synthesized in vitro based on available sequences for resveratrol synthases. Coding regions may also be obtained from genomic DNA, including or omitting intron sequences. Accumulation of RGluc is favored in plant tissues which contain the necessary biosynthetic precursors and low levels of β -glucosidases. Such conditions may be found in any plant cell, but are more likely to be present in non-stressed tissues, such as leaves constantly expressing RS driven by a constitutive promoter, rather than wounded or infected tissues which contain, release, or induce β -glucosidases.

Preferably, a resveratrol construct is made by subcloning an RS cDNA into a promoter cassette. Any promoter compatible with the selected RS cDNA can be used in the vector constructs of the present invention. It is also believed that a promoter within the plant cell which is capable of initiating transcription of the RS cDNA can be utilized, if the RS gene is integrated into the plant genome downstream of a transcription start site. Promoters which drive high levels of transcription in biosynthetically active plant cells during all stages of development are most likely to produce maximum levels of RGluc. For production of RGluc in plant tissues for direct human consumption, promoters must be selected to drive expression in edible portions of the plants. Upstream (5') and downstream (3') untranslated sequences must also be included to ensure sufficient translation initiation and transcript processing (polyadenylation); these sequences can be derived from RS cDNAs or genomic clones, or from commonly available plant genes and transformation vectors.

5 The resulting transgene cassette is subsequently introduced into the plant cell where it is integrated into the plant cell genome. For *Agrobacterium*-mediated transformation, the resveratrol construct is subcloned into a binary vector. The resveratrol coding region and other elements of the construct will be inserted between the right and left borders of the T-DNA region of the binary vector, i.e., the borders which define the DNA sequences that will be transferred from the *Agrobacterium* to the plant cells. For *Agrobacterium tumefaciens*-mediated transformation, leaf disc transformation and regeneration methods are preferred, but other methods such as vacuum infiltration of plants are also possible. The same binary vectors can be used for *Agrobacterium rhizogenes*-mediated transformation, resulting in transformed cells, hairy roots, or regenerated plants. Other methods of introducing the transgene cassette into the living plant cell can be used, including but not limited to; biolistic particle bombardment, pollen transformation; protoplast electroporation; or permeabilization.

15 Several methods known in the art can be used to distinguish the progeny exhibiting stable inheritance of the transgene. For transgenic plants wherein the transgenic cassette contains both the RS cDNA and a gene coding for a visible phenotypic change, the selection can be based upon visual examination of the progeny. For plant transformations involving a selectable marker gene, the appropriate selectable agent can be applied to the plants to select the transformants. Optionally, Southern blot analysis or PCR analysis can be used to verify the presence of the transferred gene in the genome of the transformed plants. RNA gel blot analysis, RT-PCR, or similar techniques can be used to verify the transcription of the RS gene in transformed tissues. Progeny which are stably transformed with the RS construct and successfully accumulating RGluc can be identified by chemically analyzing the plant tissues for the presence of RGluc, using chemical methods including but not limited to organic extraction followed by high pressure liquid chromatography (HPLC), gas chromatography (GC), gas chromatography-mass spectrometry (GC-MS), or capillary electrophoresis (CE).

RGluc can be extracted from the plant tissue with organic solvents such as acetone or methanol or expressed from the tissues as a crude sap exudate. RGluc-containing plants, plant parts or cells can also be used in their fresh, frozen or dried form.

5 **EXAMPLE 1: Transformation of Alfalfa with Peanut RS cDNA**

Alfalfa was transformed using a peanut RS cDNA, and the resulting transgenic plants were investigated.

Plant material and greenhouse conditions

10 Alfalfa (*Medicago sativa* L.) c.v. Regen SY (Bingham, et al. 1991
"Regeneration of alfalfa hybrid Regen-Sy germplasm from tissue culture and
transformation research," *Crop Sci* 31:1098) stocks and transgenic lines were
maintained in greenhouse conditions under a 16 hour photoperiod in MetroMix
350 (The Scotts Co., Marysville, OH). Independent transgenic lines were
15 vegetatively propagated by cuttings, planted in MetroMix 350 in growth chambers
(Convion, Winnipeg, Manitoba, Canada) under a 16 hour photoperiod with 100%
relative humidity for 3 weeks.

Vector constructs and plant transformation

20 The peanut (*Arachis hypogaea*) resveratrol synthase (RS) cDNA
(nucleotides 902 to 2854 of SEQ ID NO:1 and FIG. 1A and 1B) (Tropf, et al.
1994. "Evidence that stilbene synthases have developed from chalcone synthases
several times in the course of evolution," *J Mol Evol* 38:610-618) was subcloned
into the *Nco*I and *Bam*HI sites of a CaMV-35S dual enhancer promoter cassette
pRTL2 (Restrepo, et al. 1990. "Nuclear transport of plant polyviral proteins,"
Plant Cell 2:987-998). The CaMV-35S:RS cassette was partially digested with
25 *Hind*III (SEQ ID NO:1 and FIG. 1A and 1B) and subcloned into the *Hind*III site
of the binary vector pGA482 (FIG. 2). Restriction enzyme digest and DNA
sequencing confirmed the integrity of the construct. The binary vector and vector

constructs were maintained in *E. coli* DH5I₂ (Clontech, Palo Alto, CA) and transferred by electroporation to *Agrobacterium tumefaciens* LBA4404.

Transgenic alfalfa plants were generated from the transformation and regeneration-competent alfalfa (c.v. Regen SY) (Bingham, et al. 1991. *Crop Sci* 31:1098) following a modified version of published procedures (Bingham, et al. 1975. "Breeding alfalfa which regenerates from callus tissue in culture," *Crop Sci* 15:719-721). In the modified procedure, alfalfa plants were transformed with *Agrobacterium* strain LBA4404 harboring either the pGA482 (control) or the CaMV-35S:RS construct by leaf disc method with regeneration under kanamycin selection (Oommen, et al. 1994. "The elicitor-inducible alfalfa isoflavone reductase promoter confers different patterns of developmental expression in homologous and heterologous transgenic plants," *Plant Cell* 6:1789-1803). Surviving plantlets were placed on MS media without selection (Murashige, T. and Skoog, F. 1962. "A revised media for rapid growth and bioassay with tobacco tissue culture," *Physiol Plant* 15:473-497) for an additional month before transfer to Magenta boxes (Magenta Corp. Chicago, IL) and subsequent propagation by vegetative cuttings. Rooted cuttings were transferred to MetroMix 350, placed on a misting bench for one week, and finally placed under greenhouse conditions.

Southern blot and PCR analyses of transgenic lines

Genomic DNA was extracted from 1 gram of alfalfa green leaf tissue as described (Dellaporta, et al. 1983. "A plant DNA miniprep: version II," *Plant Mol Biol Rep* 1:19-21). Twenty micrograms of DNA were digested with *Hind*III and size fractionated by 1% agarose gel electrophoresis (Sambrook, et al. 1989. *Molecular Cloning: A Laboratory Manual*, 2nd ed., Cold Spring Harbor Laboratory Press). The gel was treated in 0.25 M HCl for ten minutes, denatured with 0.5 M NaOH/1.0 M NaCl for twenty minutes and neutralized with 0.5 M Tris-HCl/1.5 M NaCl for twenty minutes with gentle shaking and then transferred overnight by capillary action to a nylon membrane (GeneScreen Plus, DuPont, Boston, MA) in 5 x SSPE (1 x SSPE is 0.15 M NaCl, 10 mM sodium phosphate, 1 mM EDTA, pH 7.4). The DNA was covalently crosslinked to the membrane by

ultraviolet light (Stratalinker, Stratagene, La Jolla, CA). The hybridization probe was prepared by digesting the pGA482 binary vector with *Bam*HI and *Hind*III to release a fragment of *NPTII* gene. The gel-purified fragment was labeled with ³²P-dCTP via the random primer method (Prime a Gene, Promega, Madison, WI).

5 Southern hybridizations were carried out by the method of Church and Gilbert (Church, G.M. and Gilbert, W. 1984. "Genomic sequencing," *Proc Natl Acad Sci USA* 81:1991-1994) at 65°C. Independent transformants were subsequently identified by the hybridization pattern. All independent transgenic plants examined contained only one copy of the transgene cassette.

10 To identify those independent transgenic lines that successfully integrated the full length coding region, RS cDNA specific primers 5' CCATGGAAGGGGGAATTCGC 3' (SEQ ID NO:3) and 5' GAGCCATTCAGCACCTTAGC 3' (SEQ ID NO:4) were used in PCR reactions. One to two micrograms of genomic DNA were combined with 0.4μM (final
15 concentration) of primers, 10mM dNTPs, 1 unit of Taq-DNA polymerase (Promega, Madison, WI), in 1X PCR reaction buffer adjusted to a final volume of 50 microliters. The binary vector construct used in the transformation protocol served as a positive control reaction. Thermocycler (Singleblock System, Ericomp, Inc., San Diego, CA) conditions were as follows: denature at 95°C for 2
20 minutes, anneal at 55°C for 1.3 minutes, elongate at 72°C for 2 minutes for a total of 30 cycles, followed by a final elongation of 15 minutes at 72°C. Twenty five microliters of PCR reaction products were separated by agarose gel electrophoresis and visualized by ethidium bromide staining under UV light.

Northern blot analyses of RS and CHS transcript levels

25 Total RNA was extracted from the leaves, internodes or roots by the method of Logemann, et al. (Logemann, et al. 1987. "Improved method for isolation of RNA from plant tissues," *Anal Biochem* 163:16-20). After overnight precipitation, the protocol was modified such that the RNA was purified from the aqueous phase by the method of Zhou and Goldsbrough (Zhou, J. and

Goldsbrough, P.B. 1993. "An Arabidopsis gene with homology to glutathione S-transferase is regulated by ethylene," *Plant Mol Biol* 22:517-523). The RNA (10 µg/lane) was size fractionated by 1% agarose-formaldehyde gel electrophoresis by the method of Sambrook, et al. (Sambrook, et al. 1989. *Molecular Cloning: A Laboratory Manual*, 2nd ed., Cold Spring Harbor Laboratory Press). The RNA was transferred overnight by capillary action to a nylon membrane (GeneScreen Plus, DuPont, Boston, MA) in 5X SSPE. The hybridization conditions and radio-labeling of probes were prepared as described in the previous section. For individual experiments, probes included a resveratrol synthase cDNA from peanut (Tropf, et al. 1994. *J Mol Evol* 38:610-618), a chalcone synthase cDNA (Junghans, et al. 1993. "Stress responses in alfalfa (*Medicago sativa* L.) 15. Characterization and expression patterns of members of a subset of the chalcone synthase multigene family," *Plant Mol Biol* 22:239-253) and hybridized with the plant 18S ribosomal RNA probe (Eckenrode, et al. 1985. "Comparison of the nucleotide sequence of soybean 18S rRNA with the sequences of other small-subunit rRNAs," *J Mol Evol* 21: 259-269) as a loading control.

High levels of RGluc accumulate in the young leaves (approximately 150 µg/g fresh weight) and in the old internodes (approximately 130 µg/g fresh weight) of the highest accumulating alfalfa lines expressing RS. However, HPLC analyses of root extracts detected only marginal levels of RGluc (<2.0 µg/gram fresh weight) in these same independent lines (data not shown). Alfalfa roots are known to accumulate high constitutive levels of flavonoids and isoflavonoids (Oommen, et al. 1994. *Plant Cell* 6:1789-1803), and CHS would be a direct competitor of metabolic intermediates p-coumaroyl CoA and malonyl CoA. Therefore, northern blot experiments were performed to compare the relative transcript levels of RS and CHS in the leaves, internodes and roots of three independent CaMV35S:RS lines and a vector control line. Results in FIG. 3A and FIG. 3B show that the highest levels of RS transcripts are found in the leaves and internodes while comparatively low levels were detected in the roots (lanes 1-3). As expected, no RS transcripts were detected in the vector control (lane C)(FIG. 3A). In contrast, the highest CHS message levels were detected in the roots

compared to the leaves and internodes (FIG. 3B). Therefore, the nearly undetectable levels of RGluc in the roots are due to a combination of relatively low RS transcript levels and strong competition for the available substrate pool of high levels of CHS.

5 **Characterization and RGluc identification by HPLC analysis**

Independent transgenic alfalfa lines harboring the CaMV35S:RS construct were analyzed for the presence of resveratrol by reverse phase C18 HPLC analyses (4.6 X 250mm column, Baker, Phillipsburg, NJ). Metabolites were extracted from 0.5–1.0 grams of fresh leaves, internodes or roots in 100% acetone for up to two days. The supernatant was dried completely under nitrogen and dissolved in 0.7 ml of methanol followed by 0.3 ml water. The sample was vortexed vigorously, sonicated for 5 minutes and then centrifuged to remove the insoluble debris. The final supernatant was concentrated to dryness then dissolved in 0.1 ml of methanol. For analysis, 20 µl of sample was injected and metabolites separated by a 45 minute linear gradient from 20–60% solvent B (solvent A = 1.0% H₃PO₄, solvent B = 100% acetonitrile) with a flow rate of 0.8 ml/min monitored at λ=320nm. UV spectra of peaks of interest were recorded with a UV diode array detector (Beckman Instruments, Fullerton, CA). Characterization of the putative resveratrol-conjugate was performed by β-glucosidase digestion of a crude leaf extract. The methanol was removed under nitrogen and the residue dissolved in 200µl of 25mM citric acid/phosphate buffer (pH=5.2) containing 0.5 mg/ml β-glucosidase from almonds (Sigma Chemical Co., St. Louis, MO). After incubation at 37°C for 1 hour, the free resveratrol was extracted from the aqueous phase 3 times with an equal volume of ethyl acetate. The ethyl acetate was pooled and concentrated to dryness under nitrogen, dissolved in methanol, and then analyzed by HPLC. The identity of resveratrol was confirmed by co-chromatography with a resveratrol standard (Sigma) and by comparison of UV absorbance spectra.

Independent transgenic alfalfa lines harboring the CaMV35S:RS construct as evidenced by Southern blot and PCR analyses were analyzed by HPLC for the

constitutive accumulation of resveratrol. Results shown in FIG. 4 reveal the presence of an unknown peak (8.2 minutes) that appears only in the leaves and internodes of lines transformed with the CaMV35S:RS binary vector (chromatogram A) and not vector control plants (chromatogram B). The UV spectra analysis of the 8.2 minute peak and a resveratrol standard are nearly identical with absorbance maxima of 307 nm and 320 nm for both compounds (FIG. 5). However, the 8.2 minute retention time is significantly less than the retention time observed with a resveratrol standard (14.9 minutes). This result shows that the resveratrol had been modified by the addition of hydrophilic moiety, possibly a sugar. Hydrolysis with β -glucosidase of the unknown compound results in the appearance of free resveratrol (FIG. 6). In addition, removal of H_3PO_4 from the aqueous phase of HPLC solvent system did not alter the retention time of the resveratrol conjugate (data not shown). This observation shows that the sugar moiety was not substituted with a charged group such as malonic acid.

1H and ^{13}C NMR analyses of RGluc

The suspected resveratrol glucoside conjugate was purified from several kilograms of transgenic alfalfa leaves and internode tissue. Large volumes of crude acetone extracts were concentrated to near dryness under vacuum.

Insoluble materials were removed by centrifugation with the remaining supernatant adjusted to 50% methanol. The extract was passed over C18 reverse phase disposable cartridge (SepPak, Waters Corp, Milford, MA) followed by concentration to near dryness under vacuum to remove the methanol. The aqueous phase was extracted 3 times with an equal volume of ethyl acetate. The ethyl acetate fractions were pooled and concentrated to dryness under vacuum. The final residue was dissolved in methanol. The resveratrol-conjugate was then purified by preparative C18 reverse phase HPLC (22.5 x 250mm, Econosil, Deerfield, IL). For purification, 0.5 ml of extract was separated by a 45 minute linear gradient from 10-25% solvent B (solvent A = water, solvent B = acetonitrile) at a flow rate of 20 ml/minute monitored a $\lambda = 320nm$. Fractions

containing the resveratrol conjugate were pooled, concentrated to dryness under nitrogen and purified a second time. The final fraction was concentrated to dryness and dissolved in a small volume of methanol. The concentration was estimated by comparison of the absorbance spectra to a known concentration of the resveratrol standard. The sample to be analyzed was dried under nitrogen and analyzed by ^{13}C NMR (150MHz, CD_3OD) and ^1H NMR (600 MHz, CD_3OD). Identity was confirmed by comparison to previously published reports (Mattivi, et al. 1995. *J Agric Food Chem* 43:1820-1823; Waffo-Teguo, et al. 1998. *J Nat Prod* 61:655-657).

Data obtained from ^{13}C -NMR and ^1H -NMR given in Tables I and II below were highly consistent with previous reports which identified this compound as trans-resveratrol-3-O- β -glucopyranoside, commonly known as piceid or polydatin (Waterhouse, A.L. and Lamuela-Reventost, R.M. 1994. "The occurrence of piceid, a stilbene glucoside in grape berries," *Phytochemistry* 37:571-573; Mattivi, et al. 1995. *J Agric Food Chem* 43:1820-1823; Waffo-Teguo, et al. 1998. *J Nat Prod* 61:655-657). Table I contains ^{13}C NMR values for the RGluc purified from transgenic alfalfa (in column RS-X) compared with published values for resveratrol glucoside purified from two non-transgenic plants (Waffo Teguo, et al. 1998. "Isolation, identification, and antioxidant activity of three stilbene glucosides newly extracted from *Vitis vinifera* cell cultures," *J Nat Prod* 61:655-657; and Mattivi, et al. 1995. "Isolation, characterization, and evolution in red wine vinification of resveratrol monomers," *J Agri Food Chem* 43:1820-1823). Table II contains proton NMR values for the RGluc purified from transgenic alfalfa (in column RS-X) compared with published values for resveratrol glucoside purified from a non-transgenic plant (Waffo Teguo, et al. 1998. *J Nat Prod* 61:655-657).

In preliminary experiments, HPLC analyses of shoots collected from independent transgenic alfalfa lines found that the concentrations of RGluc ranged

**Table I: Comparison of ^{13}C -NMR Chemical Shift Values
(150 MHz, CD_3OD) for Isolated Resveratrol Conjugate
with Values from Two Published Studies**

C^{a}	δ (RGluc)	δ^{b}	δ^{c}
1	141.43	141.4	140.9
2	107.05	107.0	106.2
3	160.47	160.5	160.2
4	104.13	104.1	103.9
5	159.58	159.6	159.4
6	108.38	108.4	108.2
7	126.69	126.7	126.5
8	129.99	130.0	129.9
1'	130.34	130.3	130.0
2',6'	128.91	128.9	128.9
3',5'	116.50	116.5	116.4
4'	158.47	158.5	158.2
<u>Glucose</u>			
1''	102.43	102.4	102.1
2''	74.97	75.0	74.8
3''	78.07	78.1	78.1
4''	71.51	71.5	71.5
5''	78.25	78.3	77.8
6''	62.62	62.6	62.8

- 5 ^a Carbon assignments as reported by Mattivi *et al.*
^b Values reported by Teguo *et al.* (1996).
^c Values reported by Mattivi *et al.* (1995).

**Table II: Comparison of ^1H -NMR chemical shift values
(600 MHz, CD_3OD) for the isolated resveratrol
conjugate with published values**

Proton Assignment (Teguo) ^a	$\delta(\text{RGluc})$	δ^b
H-2', H-6'	7.35 (2H, d)	7.35 (2H, d)
H-8	7.01 (1H, d)	7.00 (1H, d)
H-7	6.84 (1H, d)	6.84 (1H, d)
H-2	6.78 (1H, br s)	6.78 (1H, br s)
H-3', H-5'	6.76 (2H, d)	6.76 (2H, d)
H-6	6.61 (1H, br s)	6.61 (1H, br s)
H-4	6.45 (1H, br s)	6.44 (1H, br s)
Glc H-1''	4.89 (1H, d)	4.88 (1H, d)
Glc H-6a''	3.92 (1H, dd)	3.92 (1H, dd)
Glc H-6b''	3.71 (1H, dd)	3.70 (1H, dd)
Glc H-2'', H-3'', H-4'', H-5''	3.48 - 3.38 (4H, m)	3.48 - 3.38 (4H, m)

^a Proton assignments as reported by Teguo *et al.* (1996)

^b Values reported by Teguo *et al.* (1996).

from 5.0 - 20.0 $\mu\text{g}/\text{gram}$ fresh weight, measured as resveratrol equivalents.

However, these data were significantly variable for replicate samples taken from the same independent lines. Therefore, an experiment was performed to test whether the concentration of the RGluc was developmental or tissue dependent.

Independent alfalfa lines that showed consistently high levels of RGluc were grown under greenhouse conditions. The leaves and internodes from several shoots were harvested, pooled and extracted for HPLC analysis according to their relative age and position on individual alfalfa shoots. For example, L-1 was considered the youngest leaf (FIG. 7). Results show that the concentration of RGluc in the leaves declines significantly from the youngest to the oldest leaves on a $\mu\text{g}/\text{gram}$ fresh weight basis (FIG. 8). In contrast, the concentrations increase significantly from the youngest internodes to the oldest. Similar results were

obtained in two additional RGluc-accumulating lines (data not shown). Northern blot analyses taken from the same independent line indicated that the relative level of RS transcripts were not significantly affected by the age or tissue type (FIG. 9). Taken together, these data demonstrate there is no correlation between RS transcript levels and extractable levels of RGluc in these tissues. The concentration of RGluc in these tissues is dependent upon the relative availability of metabolic intermediates, p-coumaroyl CoA and malonyl CoA.

Agar-plate bioassay and plant-pathogen interactions

The alfalfa fungal pathogen *Phoma medicaginis* Malbr. & Roum. var. *medicaginis* (Leath, K.T., "Spring black stem and leaf spot." In *Compendium of Alfalfa Diseases*, D.L. Stuteville & DC Erwin, 2nd ed., American Phytopathological Society Press, 1990, p.16-17) maintained on potato dextrose agar (PDA, Difco Laboratories, Detroit, MI) for one month in a dark growth chamber at 22°C. Agar-plate bioassays were performed by dissolving resveratrol or RGluc purified from transgenic alfalfa lines in 50 µl of ethanol. The concentration of RGluc (measured in resveratrol equivalents) was estimated by HPLC analysis and comparison to a known concentration of a resveratrol standard. The ethanol solution was added to molten PDA such that the final molar concentrations of resveratrol or RGluc were 0.18 mM (50µg/ml resveratrol or 85 µg/ml for RGluc). For this experiment, control plates were made whereby an equal volume of ethanol was added to PDA without resveratrol. A small agar plug of *P. medicaginis* was placed in a petri dish containing the resveratrol-PDA mixture, sealed with parafilm and placed in a dark grown chamber at 22°C. The extent of hyphal growth was measured after one week.

To test for resistance in the transgenic lines, the first and second trifoliate leaves of greenhouse grown transgenic alfalfa lines were wound inoculated with a 27.5 gauge syringe needle dipped in a *P. medicaginis* spore suspension. The number of colony forming units per ml (CFU/ml) was estimated by plating a serial dilution of the spore suspension on PDA. After inoculation, the stem was cut at the fourth internode and placed in a magenta box, with the cut end imbedded in

0.8% water agar (Phytagar, Difco, Detroit, MI). The magenta box was sealed with parafilm to maintain 100% humidity and placed in a growth room (16 hour photoperiod, 22°C) where disease symptoms were allowed to develop for 8 to 10 days. The extent of necrosis around the wound sites was measured with a digital video imaging system (Ultra-Lum, Inc., Paramount, CA) and analysis software (Scion Image for Windows, Frederick, MD).

To determine the extent of hyphal growth and the formation of reproductive structures, excised leaves were placed in 100% humidity for up to three days followed by staining with a trypan blue/ethanol solution (Keogh, et al. 1980. "Comparison of histological and physiological responses to *Phykospora pachyrhizi* in resistant and susceptible soybeans," *Trans Br Mycol Soc* 74:329-333). Briefly, the leaves were completely covered with the trypan blue staining solution (10 ml lactic acid; 10 ml Tris-equilibrated phenol, pH 7.4; 10 ml glycerol; 10 ml water; 10 mg trypan blue; Sigma) followed by an equal volume of 100% ethanol. The samples were boiled for five minutes, and then allowed to cool at room temperature for up to 24 hours. For destaining, the staining solution was discarded, 0.8 g/ml of chloral hydrate was added followed by boiling for three minutes. The chloral hydrate was discarded, and the leaves rinsed well with water and stored in 50% glycerol solution. Fungal hyphae and pycnidia were examined with a dissecting microscope (Model SMZ-10, Nikon, Japan) and photographed with Ektachrome 160T color slide film (Eastman Kodak, Rochester, NY) with a Nikon FX-35WA 35mm camera.

Prior to the transformation experiments, agar-plate bioassays were used to test a resveratrol standard for anti-fungal activity against several alfalfa pathogens. Results showed that an isolate of *Phoma medicaginis* was the most sensitive (data not shown). RGluc was purified by preparative HPLC from transgenic lines and tested in agar plate bioassays in order to assess its effectiveness against this same isolate. Results showed that hyphal growth was significantly reduced (>50%) in the presence of RGluc (85 µg/ml) or resveratrol (50 µg/ml). Three replicates of this experiment were performed. Importantly, the concentration of RGluc

determined by HPLC analysis of the transgenic alfalfa lines is significantly higher to that used in these bioassays. Therefore, a sufficient concentration of RGluc should be available to inhibit pathogen ingress and reduce disease symptoms.

Two independent alfalfa lines that consistently accumulate the highest levels of RGluc and two independent pGA482 vector control lines were tested for resistance to *P. medicaginis*. First (L1) and second trifoliolate (L2) leaves (FIG. 7) were wound-inoculated with small gauge needles that were dipped in spore suspensions varying from 10^4 to 10^7 colony forming units (CFU/ml). After ten days, the brown necrotic zone surrounding the wound site was measured. Results in FIG. 10 and FIG. 11 show that over the range of CFU's tested, the area (mm^2) of tissue necrosis is reduced on average by as much as 50% as compared to the vector control plants. In addition, the observed area of chlorosis surrounding the necrotic zone also appeared to be greatly reduced. (FIG. 12A and FIG. 12B).

Further evidence of increased resistance to *P. medicaginis* was found after the detached leaves that appeared to be the most resistant (10^4 CFU/ml; FIG. 10 and FIG. 11) were allowed to incubate at 100% relative humidity. After three days, the leaves were stained with trypan blue in order to visualize the extent of hyphal ingress. Results in FIG. 12C show extensive hyphal growth in the vector control line and the formation of reproductive structures (pycnidia). In contrast, only a small area of fungal hyphae (blue staining) outside of the necrotic zone could be observed in inoculated leaves from a CaMV35S:RS transgenic line (FIG. 12D). Subsequently, the extent of hyphal ingress outside of the necrotic zone surrounding the wound site and the number of pycnidia were measured. Results in FIG. 13 show the extent of hyphal ingress and number of pycnidia formed beyond the necrotic zone is much greater in the vector control lines than in the CaMV35S:RS lines. In only seven out of fifty-seven lesions examined from the CaMV35S:RS lines could pycnidia be identified, compared to forty-seven out of fifty lesions from the vector controls. Together these experiments demonstrate that the accumulation of RGluc is sufficient to reduce the extent of leaf necrosis,

prevent chlorosis caused by hyphal ingress and reduce the number of reproductive structures.

EXAMPLE 2: *Agrobacterium*-mediated Transformation of Soybean

In soybean, the CaMV-35S:RS binary construct or the pGA482 binary
5 vector control plasmid was introduced into *Agrobacterium rhizogenes* Strain
K599 (Savka, et al. 1990. *Phytopathology* 80:503-508) using a standard freeze-
thaw technique. *A. rhizogenes* colonies containing the binary vector were selected
on YMB agar plates with kanamycin (25 mg/l) and tetracycline (12 mg/l). The
composition of the YMB agar plates per liter was 0.45 grams anhydrous dibasic
10 potassium phosphate, 0.2 grams magnesium sulfate (7H₂O), 0.1g sodium chloride,
10 g mannitol, and 0.4g yeast extract. Components were dissolved in distilled
water, the pH adjusted to 6.5, 15 g of bacteriological grade agar (Bactoagar,
Gibco, Rockville, MD) was added, and the mixture was sterilized by autoclaving
for thirty minutes at 121°C. After cooling to approximately 50°C, the appropriate
15 antibiotics were added and poured into sterile plastic petri plates. Selected
colonies were re-streaked onto fresh plates and used for inoculum.

Soybean seeds (*Glycine max* cv. Harosoy 63) were surface sterilized with
70% ethanol for ten minutes and 20% bleach at a final concentration of
approximately 1% sodium hypochlorites for twenty minutes, and then rinsed three
20 times with sterile distilled water. Surface sterilized seeds were then placed on
sugar-water-agar (SWA) plates for germination at 23-25°C with 16 hour light/8
hour dark, with cool-white fluorescent bulbs providing illumination. SWA
contains 0.8% Gibco tissue culture grade Phytagar, 0.5% sucrose in distilled water
which was autoclaved for 30 minutes, cooled to 50°C, and then poured into 150
25 mm by 25 mm transparent plastic Petri dishes or pre-sterilized Magenta boxes.).

The cotyledons of nine to eleven-day-old soybean seedlings were wounded
using a sharp scalpel dipped into the *Agrobacterium rhizogenes* mass growing on
the surface of the YMB plates described above. The seedlings were transferred to
transparent plastic Magenta boxes (Magenta Corp, USA, Chicago, IL) containing

SWA medium, with roots embedded in the medium to hold the seedlings upright. The first morphogenic change, detected at 5-10 days after inoculation, was callus formation at the inoculation sites. Within two weeks, the first roots were visible; they grew directly out of the callus. The number of roots produced varied from four to nine per inoculated cotyledon after 3 weeks. Plants wounded with a sterile scalpel (uninoculated control) did not form roots at the wound site.

Approximately 50 to 60% of the emerging hairy roots were "co-transformed" (contain both the Ri DNA from the genome of the *A. rhizogenes* and the T-DNA region of the introduced binary vector). Individual hairy roots were transferred to Schenk & Hildebrandt (SH) agar medium supplemented with phytohormones (Oommen et al. 1994. *Plant Cell* 6:1789-1803) and carbenicillin (500 mg/ml) to initiate callus from the roots and to eliminate any *A. rhizogenes*. The hairy roots and newly initiated calli were transferred to fresh medium at weekly intervals.

Four to five weeks after initiation, calli were aseptically sampled (100mg) and analyzed for the presence of the NPT II gene using an NPT II ELISA kit (5Prime3Prime Inc., Boulder, CO). Calli induced by *A. rhizogenes* with no binary vector were negative for NPT II ELISA. Calli positive by this ELISA assay contained at least part of the T-DNA region from the binary vector. After further increases in the calli mass, these positive calli (and representative non-transformed calli) were then assayed for the presence of RGluc and the presence of the CaMV-35S:RS construct, using the techniques similar to those used for the transgenic alfalfa. From each pGA482 vector control and CaMV-35S:RS transgenic callus line, approximately 25 grams of soybean callus cells were aseptically removed from the culture dish, and submerged in 150 ml acetone to extract the phenolic compounds. After two days shaking, the mixture was centrifuged, the acetone extract taken to dryness on a rotary evaporator unit, and the residue dissolved in methanol. After centrifugation, this extract was analyzed by HPLC, as described for the alfalfa extracts.

Stilbenes have not been reported to accumulate in soybean plants, seeds, cell cultures or food products. No RGluc was observed in the control (nontransformed soybean callus extracts). A new peak was present in the HPLC chromatograms for CaMV-3S:RS transformed calli. This new compound was identified as RGluc, based on the observation that its properties were identical to the RGluc from alfalfa (identical HPLC retention time, lack of change in retention time which mobile phase component is changed from 1% H₃PO₄ to pure H₂O, identical UV diode array scan, UV scan similar to free resveratrol, ability to be hydrolyzed to free resveratrol by beta-glucosidase, etc.)(FIG. 14). FIG. 14 shows the HPLC chromatogram of a transgenic soy callus with a RGluc peak at 27 minutes. FIG. 15 shows the HPLC chromatogram of a non-transgenic soy callus line. To enhance the resolution of the RGluc from the endogenous soybean cell phenolics in crude extracts as in FIG. 14, the gradient was altered from that used for alfalfa plants extracts. The gradient for crude soy extracts was 90% water/10% CH₃CN initially with a linear change to 25% CH₃CN in 45 minutes. FIG. 16 is the UV diode array scan of the soybean callus-generated RGluc peak, which matches closely the alfalfa-generated peak (FIG. 5). FIG. 17 shows the RGluc partially purified from soy callus before treatment with 1 mg beta-glucosidase, and FIG. 18 shows the RGluc partially purified from soy callus after treatment with 1 mg beta-glucosidase (from almonds; Sigma, St. Louis) for 45 minutes in pH5.5 citrate/phosphate buffer. Samples in FIG. 17 and FIG. 18 were generated using the same extraction, purification, and HPLC analytical methods as were used for the transgenic RGluc alfalfa studies. RGluc was eluted at approximately 8 minutes and the resveratrol was eluted at approximately 15 minutes.

These transgenic plant cell callus cultures, or those of a similarly transformed species, can be grown axenically for years as callus or as cell suspension cultures to produce large quantities of RGluc-containing cells for direct use, or for the production of extracts containing RGluc, or for the production of purified RGluc.

EXAMPLE 3: RGluc-producing Transgenic Alfalfa Diet for Mouse

Because alfalfa is a highly nutritious animal feed, a study was carried out to compare the chemopreventative activity of a basal diet and a diet supplement with dried transgenic RGluc accumulating alfalfa.

5 The transgenic alfalfa was dried for 24-48 hours in a convection oven, powdered in a cyclone grinding mill to a particle size of less than one millimeter, and then blended at a rate of 20% weight/weight into the basic diet, which was then formed into food pellets. Four replicate samples of the dried powdered alfalfa was extracted with 90% acetone/10% water for a 24 hour period. The
10 extract was taken to dryness and resuspended in methanol and subjected to HPLC analysis for RGluc. The powdered alfalfa contained 162 micrograms RGluc (equivalent on a molar basis to approximately 95 micrograms resveratrol).

 The assay used was the mouse aberrant crypt foci (ACF) system (Olivo, S. and Wargovich, M.J. 1998. "Inhibition of aberrant crypt foci by chemopreventive
15 agents," *Vivo-Attiki* 12:159-166.). Mice were injected with varying levels of tumor-inducing compound azoxymethane (AOM; 10 mg/kg body weight weekly) for five weeks while being fed basal diet, the mice were then fed test diets for five weeks, and the number of putative precancerous lesions in the colon (ACF) in the colon were subsequently recorded. Mice in the group receiving the RGluc-alfalfa
20 supplemented diet consumed approximately $4.8 \pm .2$ grams per day, which indicates an average dose of 155 micrograms of RGluc per day (or 91 micrograms resveratrol per day), which translates to approximately 4.7 mg RGluc per kg body weight (or 2.8 mg resveratrol per kg body weight). Preliminary experiments indicate that supplementation of the basal diet with 10 and 20% (weight/weight)
25 powdered alfalfa did not significantly affect the body weight or food consumption, indicating that the diets were well matched in nutritional qualities and caloric content.

 Mice receiving the control diet achieved an average body weight of 31.3 g \pm 1.3 g and were found to have an average of 30.8 ± 10.2 foci/colon. Mice

receiving the RGluc-alfalfa supplemented diet achieved an average body weight of $32.8 \text{ g} \pm 2.2 \text{ g}$ and were found to have an average of 21.6 ± 5.5 foci/colon.

Compared to ACF numbers in mice fed a basal (control) diet, a significant reduction in ACF number was noted when mice were fed a diet supplement with dried transgenic RGluc accumulating alfalfa. These results indicate that the a diet supplemented with dried transgenic RGluc accumulating alfalfa inhibited colon carcinogenesis in mammals.

It is to be understood that the above description is of preferred exemplary embodiments of the invention and is intended to be illustrative of the invention, but is not to be construed to limit the scope of the invention in any way.

Modifications may be made in the structural features of the invention without departing from the scope of the invention. It will be readily apparent to those skilled in the art that alternative materials may also be utilized without departing from the scope of the invention.

WE CLAIM:

1. Edible plant material comprising transgenic plant cells transformed with a resveratrol synthase transgene under the control of a constitutive promoter whereby said transgenic plant cells accumulate resveratrol glucoside upon expression of said resveratrol synthase transgene, wherein said edible plant material exhibits an increased
5 concentration of resveratrol glucoside at the time of consumption as compared to edible plant material consisting of non-transgenic plant cells of the same cell type grown under the same conditions.
2. The edible plant material of Claim 1, wherein said edible plant material is suitable for consumption as a food stuff, a nutritional supplement, an animal feed supplement, or a nutraceutical in the form of a live or harvested whole plant or plant part.
3. The edible plant material of Claim 1, wherein said resveratrol synthase transgene is SEQ ID NO:2.
4. The edible plant material of Claim 2, wherein said resveratrol synthase transgene is SEQ ID NO:2.
5. The edible plant material of Claim 1, 2, 3 or 4, wherein said plant is a legume.
6. The edible plant material of Claim 5, wherein said plant is alfalfa.
7. The edible plant material of Claim 5, wherein said plant is soybean.
8. A composition comprising edible plant material, said edible plant material comprising transgenic plant cells transformed with a resveratrol synthase transgene under the control of a constitutive promoter whereby said transgenic plant cells accumulate resveratrol glucoside upon expression of said resveratrol synthase transgene, wherein the
5 percentage of resveratrol glucoside in said composition obtained by adding a given weight of said edible plant material comprising said transgenic plant cells to said composition is higher than the percentage of resveratrol glucoside obtainable by adding instead the same weight of edible plant material consisting of non-transgenic plant cells of the same cell type grown under the same conditions to said composition.
9. The composition of Claim 8, wherein said composition is suitable for consumption as a food stuff, a nutritional supplement, an animal feed supplement, or a nutraceutical.

10. The composition of Claim 8, wherein said resveratrol synthase transgene is SEQ ID NO:2.

11. The composition of Claim 9, wherein said resveratrol synthase transgene is SEQ ID NO:2.

12. The composition of Claim 8, 9, 10 or 11, wherein said plant is a legume.

13. The composition of Claim 12, wherein said plant is alfalfa.

14. The composition of Claim 12, wherein said plant is soybean.

5 15. An edible plant comprising transgenic plant cells transformed with a resveratrol synthase transgene under the control of a constitutive promoter whereby said transgenic plant cells accumulate resveratrol glucoside upon expression of said resveratrol synthase transgene, wherein said edible plant exhibits an increased concentration of resveratrol glucoside at the time of consumption as compared to an edible plant comprising non-transgenic plant cells of the same cell type grown under the same conditions.

16. The edible plant of Claim 15, wherein said edible plant is suitable for consumption as a food stuff, a nutritional supplement, an animal feed supplement, or a nutraceutical in the form of a live or harvested whole plant or a plant part.

17. The edible plant of Claim 15, wherein said resveratrol synthase transgene is SEQ ID NO:2.

18. The edible plant of Claim 16, wherein said resveratrol synthase transgene is SEQ ID NO:2.

19. The edible plant of Claim 15, wherein said resveratrol synthase transgene comprises at least one recombinant DNA sequence.

20. The edible plant of Claim 16, wherein said resveratrol synthase transgene comprises at least one recombinant DNA sequence.

21. The edible plant of Claim 15, 16, 17, 18, 19 or 20, wherein said plant is a legume.

22. The edible plant of Claim 21, wherein said plant is alfalfa.

23. The edible plant of Claim 21, wherein said plant is soybean.

24. Seed from the edible plant of Claim 15, 16, 17, 18, 19, 20, 21, 22 or 23.

25. Progeny from the edible plant of Claim 15, 16, 17, 18, 19, 20, 21, 22 or 23.

26. Progeny from the seed of Claim 24.

27. A method of improving the nutritional value of an edible plant comprising:
transforming cells from said plant with a DNA construct comprising at least one
open reading frame encoding for resveratrol synthase under expression control of a
constitutive promoter to form transgenic plant cells; and

5 cultivating said transgenic plant cell under conditions conducive to regeneration
and plant growth and under conditions conducive to the accumulation of p-coumaryl CoA
and malonyl CoA precursors and the suppression of β -glucosidases,

wherein said edible plant exhibits an increased concentration of resveratrol
glucoside at the time of consumption as compared to an edible plant comprising non-
10 transgenic plant cells of the same cell type grown under the same conditions.

28. The method of Claim 27, wherein said open reading frame is SEQ ID NO:2.

29. A method of using an edible plant comprising transgenic plant cells
transformed with a resveratrol synthase transgene under the control of a constitutive
promoter whereby said transgenic plant cells accumulate resveratrol glucoside upon
expression of said resveratrol synthase transgene, wherein said edible plant exhibits an
5 increased concentration of resveratrol glucoside at the time of consumption as compared
to an edible plant comprising non-transgenic plant cells of the same cell type grown
under the same conditions to provide a nutraceutical benefit to a human or animal.

30. The method of Claim 29, wherein said open reading frame is SEQ ID NO:2.

31. A method for producing isolated resveratrol glucoside comprising
transforming a non-transgenic plant cell with a DNA construct comprising at least
one open reading frame encoding for resveratrol synthase under expression control of a
constitutive promoter to form said transgenic plant cell; and

5 cultivating said transgenic plant cell under conditions conducive to regeneration
and plant growth and under conditions conducive to the accumulation of p-coumaryl CoA
and malonyl CoA precursors and the suppression of β -glucosidases, wherein said
transgenic plant cell exhibits an increased concentration of resveratrol glucoside as

compared to non-transgenic plant cells of the same cell type grown under the same
10 conditions; and

isolating said resveratrol glucoside from said transgenic plant cell.

32. The method of Claim 31, wherein said open reading frame is SEQ ID NO:2.

33. The method of Claim 31 or 32, wherein said isolated resveratrol glucoside is
suitable for consumption as a nutritional supplement, an animal feed supplement, or a
nutraceutical.

34. A method for producing a transgenic plant cell having increased resveratrol
glucoside concentration comprising

transforming a non-transgenic plant cell with a DNA construct comprising at least
one open reading frame encoding for resveratrol synthase under expression control of a
5 constitutive promoter to form said transgenic plant cell; and

cultivating said transgenic plant cell under conditions conducive to regeneration
and plant growth and under conditions conducive to the accumulation of p-coumaroyl CoA
and malonyl CoA precursors and the suppression of β -glucosidases,

10 wherein said transgenic plant cell exhibits an increased concentration of
resveratrol glucoside as compared to non-transgenic plant cells of the same cell type
grown under the same conditions.

35. The method of Claim 34, wherein said open reading frame is SEQ ID NO:2.

36. The method of Claim 34 or 35, wherein said plant is a legume.

37. The method of Claim 36, wherein said plant is alfalfa.

38. The method of Claim 36, wherein said plant is soybean.

39. A method of increasing disease resistance in an edible plant comprising
transforming cells of said plant with a resveratrol synthase transgene under the control of
a constitutive promoter whereby said transgenic plant cells accumulate resveratrol
glucoside upon expression of said resveratrol synthase transgene, wherein said edible
5 plant exhibits an increased concentration of resveratrol glucoside at the time of
consumption as compared to an edible plant comprising non-transgenic plant cells of the
same cell type grown under the same conditions.

40. The method of Claim 39, wherein said open reading frame is SEQ ID NO:2.

41. A method for decreasing spoilage of an edible plant or plant parts after harvesting comprising

before harvesting, transforming cells from said plant with a DNA construct comprising at least one open reading frame encoding for resveratrol synthase under
5 expression control of a constitutive promoter to form transgenic plant cells; and

cultivating said transgenic plant cell under conditions conducive to regeneration and plant growth and under conditions conducive to the accumulation of p-coumaroyl CoA and malonyl CoA precursors and the suppression of β -glucosidases, wherein resveratrol glucoside accumulates in said transgenic plant cells,

10 whereupon harvesting, said plant exhibits an increased concentration of resveratrol glucoside as compared to a plant comprising non-transgenic plant cells of the same cell type grown under the same conditions.

42. The method of Claim 41, wherein said open reading frame is SEQ ID NO:2.

43. Use of a plant material for the manufacture of a nutraceutical composition, said plant material comprising transgenic plant cells transformed with a resveratrol synthase transgene under the control of a constitutive promoter whereby said transgenic plant cells accumulate resveratrol glucoside upon expression of said resveratrol synthase
5 transgene, and wherein said plant material exhibits an increased concentration of resveratrol glucoside at the time of manufacture as compared to plant material comprising non-transgenic plant cells of the same cell type grown under the same conditions.

44. The use of Claim 43, wherein said resveratrol synthase transgene is SEQ ID NO:2.

45. The use of Claim 43 or 44, wherein said plant is a legume.

46. The use of Claim 45, wherein said plant is alfalfa.

47. The use of Claim 45, wherein said plant is soybean.

48. Use of a plant material for the manufacture of a nutritional supplement, said plant material comprising transgenic plant cells transformed with a resveratrol synthase transgene under the control of a constitutive promoter whereby said transgenic plant cells accumulate resveratrol glucoside upon expression of said resveratrol synthase transgene,
5 and wherein said plant material exhibits an increased concentration of resveratrol

glucoside at the time of manufacture as compared to plant material comprising non-transgenic plant cells of the same cell type grown under the same conditions.

49. The use of Claim 48, wherein said resveratrol synthase transgene is SEQ ID NO:2.

50. The use of Claim 48 or 49, wherein said plant is a legume.

51. The use of Claim 50, wherein said plant is alfalfa.

52. The use of Claim 50, wherein said plant is soybean.

53. Use of an edible plant material for the manufacture of a food stuff, said edible plant material comprising transgenic plant cells transformed with a resveratrol synthase transgene under the control of a constitutive promoter whereby said transgenic plant cells accumulate resveratrol glucoside upon expression of said resveratrol synthase transgene, and wherein said edible plant material exhibits an increased concentration of resveratrol glucoside at the time of manufacture as compared to edible plant material comprising non-transgenic plant cells of the same cell type grown under the same conditions.

54. The use of Claim 53, wherein said resveratrol synthase transgene is SEQ ID NO:2.

55. The use of Claim 53 or 54, wherein said plant is a legume.

56. The use of Claim 55, wherein said plant is alfalfa.

57. The use of Claim 55, wherein said plant is soybean.

1/19

AAGCTTGCAT	GCCTGCAGGT	CAACATGGTG	GAGCACGACA	CACTTGTCTA	CTCCAAAAAT	60

ATCAAAGATA	CAGTCTCAGA	AGACCAAAGG	GCAATTGAGA	CTTTTCAACA	AAGGGTAATA	120
TCCGGAAACC	TCCTCGGATT	CCATTGCCCA	GCTATCTGTC	ACTTTATTGT	GAAGATAGTG	180
GAAAAGGAAG	GTGGCTCCTA	CAAATGCCAT	CATTGCGATA	AAGGAAAGGC	CATCGTTGAA	240
GATGCCTCTG	CCGACAGTGG	TCCCAAAGAT	GGACCCCCAC	CCACGAGGAG	CATCGTGGAA	300
AAAGAAGACG	TTCCAACCAC	GTCTTCAAAG	CAAGTGGAAT	GATGTGTCAA	CATGGTGGAG	360
CACGACACAC	TTGTCTACTC	CAAAAATATC	AAAGATACAG	TCTCAGAAGA	CCAAAGGGCA	420
ATTGAGACTT	TTCAACAAAG	GGTAATATCC	GGAAACCTCC	TCGGATTCCA	TTGCCCAGCT	480
ATCTGTCACT	TTATTGTGAA	GATAGTGGAA	AAGGAAGGTG	GCTCCTACAA	ATGCCATCAT	540
TGCGATAAAG	GAAAGGCCAT	CGTTGAAGAT	GCCTCTGCCG	ACAGTGGTCC	CAAAGATGGA	600
CCCCCACCCA	CGAGGAGCAT	CGTGGAAAAA	GAAGACGTTC	CAACCACGTC	TTCAAAGCAA	660
GTGGATTGAT	GTGATATCTC	CACTGACGTA	AGGGATGACG	CACAATCCCA	CTATCCTTGC	720
AAGACCCTTC	CTCTATATAA	GGAAGTTCAT	TTGGAGAGGA	CCTCGAGAAT	TCTCAACACA	780
ACATATACAA	AACAAACGAA	TCTCAAGCAA	TCAAGCATTG	TACTTCTATT	GCAGCAATTT	840
AAATCATTTT	TTTTAAAGCA	AAAGCAATTT	TCTGAAAATT	TTCACCATTT	ACGAACGATA	900
GCCATGGAAG	GGGGAATTCTG	CAAGGTTCAA	AGGGCAGAAG	GTCCAGCAAC	TGTATTGGCA	960
TTTTTT						
<u>ATTGGAACAG</u>	<u>CAAATCCACC</u>	<u>GAAGTGTATT</u>	<u>GATCAGAGTA</u>	<u>CATATGCAGA</u>	<u>TTATTATTTT</u>	1020
<u>AGAGTAACCA</u>	<u>ATAGCGAACA</u>	<u>CATGACTGAT</u>	<u>CTCAAGAAGA</u>	<u>AATTTAGCG</u>	<u>CATCTGTGAG</u>	1080
<u>AGAACACAGA</u>	<u>TCAAGAACAG</u>	<u>ACATATGTAC</u>	<u>TTAACAGAAG</u>	<u>AGATACTAAA</u>	<u>AGAAAATCCT</u>	1140
<u>AACATGTGTG</u>	<u>CATACAAGGC</u>	<u>ACCGTCATTG</u>	<u>GATGCAAGAG</u>	<u>AAGACATGAT</u>	<u>GATCAGGGAG</u>	1200
<u>GTACCAAGAG</u>	<u>TTGGAAAAGA</u>	<u>GGTGCAACC</u>	<u>AAGGCCATCA</u>	<u>AGGAATGGGG</u>	<u>CCAGCCAATG</u>	1260
<u>TCTAAGATCA</u>	<u>CACATTTGAT</u>	<u>CTTCTGCACC</u>	<u>ACCAGCGGCG</u>	<u>TTGCGTTGCC</u>	<u>TGGCGTTGAT</u>	1320
<u>TACGAACTCA</u>	<u>TCGTACTTTT</u>	<u>AGGGCTGGAC</u>	<u>CCATGCGTCA</u>	<u>AGAGGTACAT</u>	<u>GATGTACCAC</u>	1380
<u>CAAGGTTGCT</u>	<u>TCGCTGGTGG</u>	<u>CACTGTCCTT</u>	<u>CGTTTGGCTA</u>	<u>AGGACTTGGC</u>	<u>TGAAAACAAC</u>	1440
<u>AAGGATGCTC</u>	<u>GTGTACTTAT</u>	<u>CGTTTGTCT</u>	<u>GAGAATACCG</u>	<u>CAGTCACTTT</u>	<u>CCGCGGTCTT</u>	1500
<u>AGTGAGACAG</u>	<u>ACATGGATAG</u>	<u>TCTTGTAGGA</u>	<u>CAAGCATTGT</u>	<u>TTGCCGATGG</u>	<u>AGCTGCTGCG</u>	1560
<u>ATTATCATTG</u>	<u>GTTCTGATCC</u>	<u>TGTGCCAGAG</u>	<u>GTTGAGAAGC</u>	<u>CTATCTTTGA</u>	<u>GCTTGTTCG</u>	1620
<u>ACCGATCAAA</u>	<u>AACTTGTCCT</u>	<u>TGGCAGCCAT</u>	<u>GGAGCCATCG</u>	<u>GTGGTCTCCT</u>	<u>TCGTGAAGTT</u>	1680
<u>GGACTTACAT</u>	<u>TCTATCTTAA</u>	<u>CAAGAGTGTT</u>	<u>CCTGATATTA</u>	<u>TTTCGCAAAA</u>	<u>TATCAATGAC</u>	1740
<u>GCGCTCAATA</u>	<u>AAGCTTTTGA</u>	<u>TCCATTGGGT</u>	<u>ATTTCTGATT</u>	<u>ATAACTCAAT</u>	<u>ATTTTGGATT</u>	1800
<u>GCACATCCTG</u>	<u>GTGGGCGTGC</u>	<u>AATTTTGGAC</u>	<u>CAGGTTGAAC</u>	<u>AGAAGGTGAA</u>	<u>CTTGAAGCCA</u>	1860
<u>GAGAAGATGA</u>	<u>AAGCCACTAG</u>	<u>AGATGTGCTT</u>	<u>AGCAATTATG</u>	<u>GTAACATGTC</u>	<u>AAGTGCCTGT</u>	1920

FIG. 1A

2/19

GTGTTCTTCA TTATGGATTT GATGAGGAAG AGGTCTCTTG AAGAAGGACT TAAAACTACC 1980
GGAGAAGGAC TTGATTGGGG TGTGCTTTTT GGCTTTGGTC CTGGTCTCAC TATTGAAACT 2040
GTCGTTCTCC GCAGTGTGGC CATATAATGC ACTTAATTAT GCATATATGC GATTGTGTTA 2100
TTTTTTAATA ATTTTCTTTG GCTCTAAAAT AAGCTAAGGT GCTGAATGGC TCATATATTA 2160
TTAGATGAGT GAAAAATTAA AAAAAGATGT CCAAAGTTAA TTCTTTATGC AAACATCATT 2220
CAATATCAAA GTCTGTAATT GTTAGTAAAA AATTATATCA AATTCTTTTC AATCGAGCAG 2280
CATAACACAT GCCTTTATTG ATTGGGTTGT AATTTAAGTC TGATTGCACT GTGCACAACA 2340
TTTCAAAAGT ATATGTCTCC TATTCTCAAT CATATGAAAC CGTTTGAGTA CACAGCATTT 2400
TTTGATAGGG TTGGTGATTT TGATTTGTTA GATTAGTTTG TTAGGGTTTG GTTTTTTATT 2460
TTTAGGGAAT TTTTATTCTA ATTTAAATAT ACTGATTTTT AGGGATTTTT GTATCTTAAA 2520
TATATGAGAG AAAAAAGTGA GACGTTAATT TCTAAAAAAA CGAGGTGCTA ATTTGGTTTCG 2580
AACAAAACCTT TGGAGAATCA ATTTGAATTA CATATGTGAA GTTTGATAAA TTATTTTGGC 2640
TATTTACTCA TAAAAAGTTA TTAAATGTGT AGTTGTATTT AACATTTTTT TTATTAACAA 2700
CGGGGTTTAA TGGTAAAAGA AAAATAAACT AAAAGACAAT ACTTGAAAAT GAGATACCGA 2760
TAAAATCAGC ATGAAGACGA AGAGAAGTAC AAAAGGATAA ATTAATGAAT TTACATTATT 2820
CATACTAAGG TAATATATTT ATTGATGGGG ATCCTCTAGA GTCCGCAAAA ATCACCAGTC 2880
TCTCTCTACA AATCTATCTC TCTCTATTTT TCTCCAGAAT AATGTGTGAG TAGTTCCCAG 2940
ATAAGGGAAT TAGGGTTCTT ATAGGGTTTC GCTCATGTGT TGAGCATATA AGAAACCCTT 3000
AGTATGTATT TGTATTTGTA AAATACTTCT ATCAATAAAA TTTCTAATTC CTAAAACCAA 3060
AATCCAGTGA CCTGCAGGCA TGCAAGCTT 3089

FIG. 1B

09/890167-02366




FIG. 2

4/19




FIG. 3A




FIG. 3B

5/19





FIG. 4

6/19

**FIG. 5**

7/19




FIG. 6

8/19




FIG. 7

09890167-072701

9/19




FIG. 8




FIG. 9

11/19




FIG. 10

12/19




FIG. 11

13/19




FIG. 12A




FIG. 12B




FIG. 12C




FIG. 12D

14/19




FIG. 13A




FIG. 13B

15/19




FIG. 14

16/19




FIG. 15

17/19




FIG. 16




FIG. 17




FIG. 18

DECLARATION AND POWER OF ATTORNEY

As a below-named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name, that I believe that I am the original, first and sole inventor (if only one name is listed below) or I believe that we are the original, first and joint inventors (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention, design or discovery entitled **TRANSGENIC PLANTS MODIFIED TO CONTAIN RESVERATROL GLUCOSIDE AND USES THEREOF**, the specification of which (check one)

- () is attached hereto; or
 (X) was filed on **January 28, 2000**, as PCT International Application Number
PCT/US00/02366
 (X) and was amended on or about April 9, 2001.

that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above; that I do not know and do not believe that said invention, design or discovery was ever known or used in the United States of America before my invention or discovery thereof, or patented or described in any printed publication in any country before my invention or discovery thereof, or more than one year prior to this application, or in public use or on sale in the United States of America more than one year prior to this application; that said invention, design or discovery has not been patented or made the subject of an inventor's certificate issued prior to the date of this application in any country foreign to the United States of America on an application filed by me or my legal representatives or assigns; and that I acknowledge the duty to disclose information of which I am aware which is material to the examiner of this application in accordance with 37 C.F.R. § 1.56(a).

I hereby claim foreign priority benefits under 35 U.S.C. § 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application(s) for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

NUMBER	COUNTRY	DATE FILED	PRIORITY CLAIMED
N/A			

I hereby claim the benefit under Title 35, United States Code, § 119(e) of any United States provisional application(s) listed below.

APPLICATION SERIAL NO.	DATE FILED
U.S. 60/117,888	January 29, 1999

I hereby claim the benefit under 35 U.S.C. § 120 of any United States Application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States Application(s) in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose material information as defined in 37 C.F.R. § 1.56(a) which occurred between the filing date of the prior application(s) and the national or PCT international filing date of this application:

APPLICATION SERIAL NO.	DATE FILED	STATUS
N/A		

I hereby appoint:

Eugenia S. Hansen	Reg. No. <u>31,966</u>
Karen L. Knezek	Reg. No. <u>39,253</u>
Rod A. Cooper	Reg. No. <u>42,436</u>

all of the firm of Sidley Austin Brown & Wood, my attorneys with full power of substitution and revocation, to prosecute this application and to transact all business in the United States Patent and Trademark Office connected therewith.

Send correspondence to:

Eugenia S. Hansen
Sidley Austin Brown & Wood
717 N. Harwood, Suite 3400
Dallas, TX 75201

Direct telephone calls to:

Eugenia S. Hansen
at (214) 981-3315
Atty. Docket No. 11137/04704

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under § 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Full name of sole or joint inventor: Nancy L. Paiva

Inventor's signature: Nancy L. Paiva

Date: July 15, 2001

Residence (City, County, State): Ardmore, Carter County, Oklahoma OK

Citizenship: United States of America

Post Office Address: HC 70, Box 100, Ardmore, Oklahoma 73401

2-00
Full name of sole or joint inventor: **John D. Hipskind**

Inventor's signature: _____

John D. Hipskind

July 18, 2001

Date: _____

Residence (City, County, State): **Durham, Durham County, North Carolina** *NC*

Citizenship: **United States of America**

Post Office Address: **9 Sagar Court, Durham, North Carolina 27703**

10/22/01 2:31:05 PM

SEQUENCE LISTING

<110> Paiva, Nancy L.
Hipskind, John D.
The Samuel Roberts Noble Foundation, Inc.

<120> TRANSGENIC PLANTS MODIFIED TO CONTAIN RESVERATROL
GLUCOSIDE AND USES THEREOF

<130> 11137/04702

<140>
<141>

<150> 60/117,888
<151> 1999-01-29

<160> 4

<170> PatentIn Ver. 2.0

<210> 1
<211> 3089
<212> DNA
<213> Arachis hypogaea

<220>
<221> CDS
<222> (904)..(2064)

<400> 1
aagcttgcat gcctgcaggt caacatggtg gagcacgaca cacttgtcta ctccaaaaat 60
atcaaagata cagtctcaga agaccaaagg gcaattgaga cttttcaaca aagggttaata 120
tcoggaacc tcctcggatt ccattgcca gctatctgtc actttattgt gaagatagtg 180
gaaaaggaag gtggctccta caaatgccat cattgcgata aaggaaaggc catcgttgaa 240
gatgcctctg ccgacagtgg tcccaaagat ggacccccac ccacgaggag catcgttgaa 300
aaagaagaag ttccaaccac gtcttcaaag caagtggatt gatgtgtcaa catggtggag 360
cacgacacac ttgtctactc caaaaatatac aaagatacag tctcagaaga ccaaagggca 420
attgagactt ttcaacaaaag ggtaatatcc ggaaacctcc tcggattcca ttgccagct 480
atctgtcact ttattgtgaa gatagtggaa aaggaagggtg gctcctacaa atgccatcat 540
tgcgataaag gaaaggccat cgttgaagat gcctctgccg acagtgggtcc caaagatgga 600
ccccaccca cgaggagcat cgtggaaaaa gaagacgttc caaccacgtc ttcaaagcaa 660
gtggattgat gtgatatttc cactgacgta agggatgacg cacaatccca ctatccttgc 720
aagacccttc ctctatataa ggaagttcat ttggagagga cctcgagaat tctcaacaca 780
acatatataa aacaaacgaa tctcaagcaa tcaagcattc tacttctatt gcagcaattt 840

aaatcatttc ttttaaagca aaagcaattt tctgaaaatt ttcaccattt acgaacgata 900
 gcc atg gaa ggg gga att cgc aag gtt caa agg gca gaa ggt cca gca 948
 Met Glu Gly Gly Ile Arg Lys Val Gln Arg Ala Glu Gly Pro Ala
 1 5 10 15
 act gta ttg gca att gga aca gca aat cca ccg aac tgt att gat cag 996
 Thr Val Leu Ala Ile Gly Thr Ala Asn Pro Pro Asn Cys Ile Asp Gln
 20 25 30
 agt aca tat gca gat tat tat ttt aga gta acc aat agc gaa cac atg 1044
 Ser Thr Tyr Ala Asp Tyr Tyr Phe Arg Val Thr Asn Ser Glu His Met
 35 40 45
 act gat ctc aag aag aaa ttt cag cgc atc tgt gag aga aca cag atc 1092
 Thr Asp Leu Lys Lys Lys Phe Gln Arg Ile Cys Glu Arg Thr Gln Ile
 50 55 60
 aag aac aga cat atg tac tta aca gaa gag ata cta aaa gaa aat cct 1140
 Lys Asn Arg His Met Tyr Leu Thr Glu Glu Ile Leu Lys Glu Asn Pro
 65 70 75
 aac atg tgt gca tac aag gca ccg tca ttg gat gca aga gaa gac atg 1188
 Asn Met Cys Ala Tyr Lys Ala Pro Ser Leu Asp Ala Arg Glu Asp Met
 80 85 90 95
 atg atc agg gag gta cca aga gtt gga aaa gag gct gca acc aag gcc 1236
 Met Ile Arg Glu Val Pro Arg Val Gly Lys Glu Ala Ala Thr Lys Ala
 100 105 110
 atc aag gaa tgg ggc cag cca atg tct aag atc aca cat ttg atc ttc 1284
 Ile Lys Glu Trp Gly Gln Pro Met Ser Lys Ile Thr His Leu Ile Phe
 115 120 125
 tgc acc acc agc ggc gtt gcg ttg cct ggc gtt gat tac gaa ctc atc 1332
 Cys Thr Thr Ser Gly Val Ala Leu Pro Gly Val Asp Tyr Glu Leu Ile
 130 135 140
 gta ctt tta ggg ctg gac cca tgc gtc aag agg tac atg atg tac cac 1380
 Val Leu Leu Gly Leu Asp Pro Cys Val Lys Arg Tyr Met Met Tyr His
 145 150 155
 caa ggt tgc ttc gct ggt ggc act gtc ctt cgt ttg gct aag gac ttg 1428
 Gln Gly Cys Phe Ala Gly Gly Thr Val Leu Arg Leu Ala Lys Asp Leu
 160 165 170 175
 gct gaa aac aac aag gat gct cgt gta ctt atc gtt tgt tct gag aat 1476
 Ala Glu Asn Asn Lys Asp Ala Arg Val Leu Ile Val Cys Ser Glu Asn
 180 185 190
 acc gca gtc act ttc cgc ggt cct agt gag aca gac atg gat agt ctt 1524
 Thr Ala Val Thr Phe Arg Gly Pro Ser Glu Thr Asp Met Asp Ser Leu
 195 200 205
 gta gga caa gca ttg ttt gcc gat gga gct gct gcg att atc att ggt 1572
 Val Gly Gln Ala Leu Phe Ala Asp Gly Ala Ala Ala Ile Ile Ile Gly
 210 215 220

tct gat cct gtg cca gag gtt gag aag cct atc ttt gag ctt gtt tcg 1620
 Ser Asp Pro Val Pro Glu Val Glu Lys Pro Ile Phe Glu Leu Val Ser
 225 230 235

acc gat caa aaa ctt gtc cct ggc agc cat gga gcc atc ggt ggt ctc 1668
 Thr Asp Gln Lys Leu Val Pro Gly Ser His Gly Ala Ile Gly Gly Leu
 240 245 250 255

ctt cgt gaa gtt gga ctt aca ttc tat ctt aac aag agt gtt cct gat 1716
 Leu Arg Glu Val Gly Leu Thr Phe Tyr Leu Asn Lys Ser Val Pro Asp
 260 265 270

att att tcg caa aat atc aat gac gcg ctc aat aaa gct ttt gat cca 1764
 Ile Ile Ser Gln Asn Ile Asn Asp Ala Leu Asn Lys Ala Phe Asp Pro
 275 280 285

ttg ggt att tct gat tat aac tca ata ttt tgg att gca cat cct ggt 1812
 Leu Gly Ile Ser Asp Tyr Asn Ser Ile Phe Trp Ile Ala His Pro Gly
 290 295 300

ggg cgt gca att ttg gac cag gtt gaa cag aag gtg aac ttg aag cca 1860
 Gly Arg Ala Ile Leu Asp Gln Val Glu Gln Lys Val Asn Leu Lys Pro
 305 310 315

gag aag atg aaa gcc act aga gat gtg ctt agc aat tat ggt aac atg 1908
 Glu Lys Met Lys Ala Thr Arg Asp Val Leu Ser Asn Tyr Gly Asn Met
 320 325 330 335

tca agt gcc tgt gtg ttc ttc att atg gat ttg atg agg aag agg tct 1956
 Ser Ser Ala Cys Val Phe Phe Ile Met Asp Leu Met Arg Lys Arg Ser
 340 345 350

ctt gaa gaa gga ctt aaa act acc gga gaa gga ctt gat tgg ggt gtg 2004
 Leu Glu Glu Gly Leu Lys Thr Thr Gly Glu Gly Leu Asp Trp Gly Val
 355 360 365

ctt ttt ggc ttt ggt cct ggt ctc act att gaa act gtc gtt ctc cgc 2052
 Leu Phe Gly Phe Gly Pro Gly Leu Thr Ile Glu Thr Val Val Leu Arg
 370 375 380

agt gtg gcc ata taatgcactt aattatgcat atatgcgatt gtgttatttt 2104
 Ser Val Ala Ile
 385

ttaataattt tctttggctc taaaataagc taagggtgctg aatgggtcat atattattag 2164
 atgagtga aaataaaaa agatgtccaa agttaattct ttatgcaa acatcattcaat 2224
 atcaaagtct gtaattgtta gtaaaaaatt atatcaaatt cttttcaatc gagcagcata 2284
 acacatgcct ttattgattg gggtgttaatt taagtctgat tgcaactgtgc acaacatttc 2344
 aaaagtatat gtctcctatt ctcaatcata tgaaaccggt tgagtacaca gcattttttg 2404
 ataggggttg tgattttgat ttgttagatt agtttgtag gggttggttt tttattttta 2464
 gggaattttt attctaattt aaatatactg atttttaggg atttttgtat cttaaatata 2524
 tgagagaaaa aagtgaagacg ttaatttcta aaaaaacgag gtgctaattt ggttcgaaca 2584

aaactttgga gaatcaattt gaattacata tgtgaagttt gataaattat tttggctatt 2644
 tactcataaa aagttattaa atgtgtagtt gtatttaaca ttttttttat taacaacggg 2704
 gtttaatggt aaaagaaaaa taaactaaaa gacaatactt gaaaatgaga taccgataaa 2764
 atcagcatga agacgaagag aagtacaaaa ggataaatta atgaatttac attattcata 2824
 ctaaggtaat atattttattg atggggatcc tctagagtcc gcaaaaatca ccagtctctc 2884
 tctacaaatc tatctctctc tttttttctc cagaataatg tgtgagtagt tcccagataa 2944
 gggaattagg gttcttatag ggtttcgctc atgtgttgag catataagaa acccttagta 3004
 tgtatttgta tttgtaaaat acttctatca ataaaatttc taattcctaa aaccaaaaatc 3064
 cagtgacctg caggcatgca agctt 3089

<210> 2

<211> 387

<212> PRT

<213> Arachis hypogaea

<400> 2

Met	Glu	Gly	Gly	Ile	Arg	Lys	Val	Gln	Arg	Ala	Glu	Gly	Pro	Ala	Thr
1				5				10						15	
Val	Leu	Ala	Ile	Gly	Thr	Ala	Asn	Pro	Pro	Asn	Cys	Ile	Asp	Gln	Ser
			20					25						30	
Thr	Tyr	Ala	Asp	Tyr	Tyr	Phe	Arg	Val	Thr	Asn	Ser	Glu	His	Met	Thr
			35				40					45			
Asp	Leu	Lys	Lys	Lys	Phe	Gln	Arg	Ile	Cys	Glu	Arg	Thr	Gln	Ile	Lys
	50					55					60				
Asn	Arg	His	Met	Tyr	Leu	Thr	Glu	Glu	Ile	Leu	Lys	Glu	Asn	Pro	Asn
	65				70					75					80
Met	Cys	Ala	Tyr	Lys	Ala	Pro	Ser	Leu	Asp	Ala	Arg	Glu	Asp	Met	Met
				85					90					95	
Ile	Arg	Glu	Val	Pro	Arg	Val	Gly	Lys	Glu	Ala	Ala	Thr	Lys	Ala	Ile
			100					105						110	
Lys	Glu	Trp	Gly	Gln	Pro	Met	Ser	Lys	Ile	Thr	His	Leu	Ile	Phe	Cys
		115					120						125		
Thr	Thr	Ser	Gly	Val	Ala	Leu	Pro	Gly	Val	Asp	Tyr	Glu	Leu	Ile	Val
		130				135					140				
Leu	Leu	Gly	Leu	Asp	Pro	Cys	Val	Lys	Arg	Tyr	Met	Met	Tyr	His	Gln
	145				150					155					160
Gly	Cys	Phe	Ala	Gly	Gly	Thr	Val	Leu	Arg	Leu	Ala	Lys	Asp	Leu	Ala
				165					170					175	

Glu Asn Asn Lys Asp Ala Arg Val Leu Ile Val Cys Ser Glu Asn Thr
 180 185 190
 Ala Val Thr Phe Arg Gly Pro Ser Glu Thr Asp Met Asp Ser Leu Val
 195 200 205
 Gly Gln Ala Leu Phe Ala Asp Gly Ala Ala Ala Ile Ile Ile Gly Ser
 210 215 220
 Asp Pro Val Pro Glu Val Glu Lys Pro Ile Phe Glu Leu Val Ser Thr
 225 230 235 240
 Asp Gln Lys Leu Val Pro Gly Ser His Gly Ala Ile Gly Gly Leu Leu
 245 250 255
 Arg Glu Val Gly Leu Thr Phe Tyr Leu Asn Lys Ser Val Pro Asp Ile
 260 265 270
 Ile Ser Gln Asn Ile Asn Asp Ala Leu Asn Lys Ala Phe Asp Pro Leu
 275 280 285
 Gly Ile Ser Asp Tyr Asn Ser Ile Phe Trp Ile Ala His Pro Gly Gly
 290 295 300
 Arg Ala Ile Leu Asp Gln Val Glu Gln Lys Val Asn Leu Lys Pro Glu
 305 310 315 320
 Lys Met Lys Ala Thr Arg Asp Val Leu Ser Asn Tyr Gly Asn Met Ser
 325 330 335
 Ser Ala Cys Val Phe Phe Ile Met Asp Leu Met Arg Lys Arg Ser Leu
 340 345 350
 Glu Glu Gly Leu Lys Thr Thr Gly Glu Gly Leu Asp Trp Gly Val Leu
 355 360 365
 Phe Gly Phe Gly Pro Gly Leu Thr Ile Glu Thr Val Val Leu Arg Ser
 370 375 380
 Val Ala Ile
 385

<210> 3

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR primer

<220>

<221> misc_feature

<222> (1)..(20)

<400> 3

ccatggaagg gggaattcgc

<210> 4
 <211> 20
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: PCR primer

 <220>
 <221> misc_feature
 <222> (1)..(20)
 <223> RS cDNA specific primer for PCR

 <400> 4
 gagccattca gcaccttagc

20